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Abstract
Heart failure patients face a five-year 50% mortality rate, due to impaired cardiac function
and hypertrophy of the heart. Probiotics are live microorganisms which when administered in
adequate amounts confer a health benefit on the host. Considering the established
cardiovascular benefits of some probiotics, including reduction of cholesterol and
hypertension, it was hypothesized that probiotics can improve outcomes of heart failure.
Probiotics or controls were administered orally to an animal model for heart failure. Those
receiving probiotics showed a significant improvement in cardiac hypertrophy and an
attenuation of heart failure compared to control. No changes in gut microbial composition
occurred. An in vitro model for cardiomyocyte hypertrophy examined the mechanistic action
of probiotics in preventing cardiac hypertrophy. Studies showed that probiotics confer a
direct anti-hypertrophic benefit to cardiomyocytes. These results support the hypothesis that
probiotics can improve outcomes of heart failure and present a novel treatment strategy for
heart failure.
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Chapter 1 : Introduction
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1

Focus of the thesis

The purpose of this research was to investigate the potential for probiotic lactobacilli as a
therapy for heart failure. While research has shown that lactobacilli can influence
cardiovascular health through modulating cholesterol and inflammation, a study showing
that pretreatment of animals with probiotic Lactobacillus could ameliorate damage
caused by coronary artery ligation injury and subsequent perfusion, formed the impetus
for the present thesis. Until our work, no studies had tested whether probiotic
administration post-ligation injury could improve outcomes of heart failure. Therefore,
the focus of the thesis was a series of in vivo and in vitro experiments that explored the
ability of probiotic Lactobacillus to reduce the hallmark features of heart failure, namely
ventricular remodeling and the associated cardiac hypertrophy, and to investigate what
mechanism may be involved.

1.1 Heart anatomy and physiology
The human heart is a muscular pump comprised of 4 chambers: The left and right atria,
and the left and right ventricles. Deoxygenated and nutrient-poor blood is delivered to the
heart from the superior and inferior vena cava into the right atrium. Atrial systole pushes
blood from the right atrium through the tricuspid valve and into the right ventricle.
Ventricular systole pumps blood through the pulmonary valve into the pulmonary artery,
and blood eventually reaches the lungs for gas exchange. Oxygenated blood then returns
to the heart through the pulmonary vein into the left atrium. Atrial systolic contractions
push blood through the bicuspid valve into the left ventricle (LV). The LV is the largest
and strongest chamber of the heart, and is responsible for pumping oxygenated blood into
the aorta during ventricular systole contractions. The aorta then bifurcates and delivers
oxygenated blood to tissues throughout the body.
Rhythmic muscle contractions are an involuntary event controlled by electrical impulses
originating from the sinoatrial (SA) node in the right atrium. The atrial ventricular (AV)
node relays the impulses to the Purkinje fibers of the right and LV, which coordinate
ventricular systole. In ventricular diastole, muscle relaxation and reduced volume of
blood in the ventricles allows blood to passively flow from the atria through the tricuspid
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and bicuspid valves into the right and LV respectively. This change in pressure triggers
atrial systole, and the contraction forces the remaining blood out of the atria. Ventricular
filling completes the cardiac cycle, and after the diastolic relaxation period, ventricular
systole occurs again through electrical impulses from the SA node.
The muscle tissue of the heart is called the myocardium. It is a thick, middle layer of
heart tissue enclosed by the external-most and protective pericardial layer, and the innermost endocardium. The basic cellular unit of the myocardium is the single-nucleated
cardiomyocyte. These form striated chains of sarcomeres – the basic contractile unit of
cardiac muscle. Repeating sections of sarcomeres, make up myofibrils – the basic unit of
muscle. Similar to skeletal muscle, the striation of sarcomeres is formed by alternating
thick and thin protein filaments, actin and myosin. Involuntary electrical impulses
originating at the SA node cause a depolarization of the cardiomyocyte membrane,
opening calcium ion channels.
Muscle contraction is triggered by an influx of calcium ions, allowing myosin to bind to
actin. This causes a shortening of the sarcomere, similar to the sliding filament model in
skeletal muscle. The repolarization of cellular calcium ion concentration across the
membrane causes myosin to unbind actin, resulting in muscle relaxation. Coordinated
contraction and relaxation of the myocardium allows for steady movement of blood in
and out of the chambers of the heart. This rhythmic flow of blood is required to sustain
life. As tissues throughout the body continuously consume oxygen and nutrients, it is
essential for blood to properly replenish this supply. Any mechanical dysfunction in
blood flow presents serious implications to the patient. A cardiovascular even causing a
limited oxygen supply to the heart can result in impaired cardiac function and blood
pumping. Decreased cardiac output overall puts a patient at a major health risk.

1.2

Methods for cardiovascular research

Cardiovascular research involves methods and avenues of research that range from
cardiomyocyte cell culture to human clinical trials. Each has its own unique advantages,
disadvantages and appropriate applications.
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1.2.1

Cell culture

Since the first isolation of the perfused mammalian heart in 1895, advances in cell culture
techniques have allowed direct manipulation of cardiomyocytes and provide a wealth of
knowledge in cardiac physiology1. The obvious advantage of using cardiomyocyte cell
culture is the increased versatility, reduced cost, and convenient methodology as
compared to animal or clinical studies1-3. While immortalized cardiac cell lines,
carcinoma cells, and embryonic cardiac cell lines are available, the use of primary cells
has more physiological relevance to animal studies2. Cardiomyocyte isolation, culture,
and maintenance has brought insight on cellular structure and physiology using
techniques such as microscopy, electrophysiology, calcium imaging, RNA and protein
biochemistry, and immunohistochemistry1. Primary cardiomyocytes isolated from murine
animals are most commonly used because the murine model is a widely accepted small
animal cardiac model4-6, the animals are easy to handle, relatively inexpensive, and
produce a sufficient amount of cells that can be used for studies within 24 hours of
isolation1,2. Primary cardiomyocytes are isolated from either the neonatal or adult heart,
both of which cell types are highly differentiated non-regenerating2,3,7. This allows for
pharmacological and molecular manipulation in a controlled environment without the
interference of cell division or the influence of other cell types. A caveat is the need to
harvest fresh cells for each experiment without the convenience of passing and storing
cells. Two of the major differences between the neonatal and adult cardiomyocytes lie in
isolation techniques and their distinct adaptations to culture conditions. Litters of 10-20
pups are often sufficient for neonatal cardiomyocyte studies and are less expensive than
adults8. Neonatal cardiomyocytes are generally described as easier to harvest and culture
than adult cardiomyocytes because they are less sensitive to Ca2+ in the isolation
medium2,7,8. Neonatal cardiomyocytes attach readily to culture dishes and adapt quickly
to culture conditions, as evidenced by the beating of cells as early as 2-3 days after
plating7,9. This is advantageous and important because experimentation can begin soon
after isolation, minimizing the length of time required in culture. Consistent isolation
methods and culture conditions are essential for neonatal cardiomyocyte culture because,
depending on the age of the cells, they can still possess some embryonic gene expression
and might divide in culture9,10. The gene expression and protein production of these
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immature and mitotic neonatal cardiomyocytes is different from their post-mitotic adult
counterparts, therefore comparing cells from different cultures types should be taken with
care1,9,10. Ideally the experimental design for neonatal cardiomyocyte studies requires
isolation of cardiomyocytes from litters of the exact same age and identical culture
conditions. Once this is controlled for, neonatal cardiomyocytes are very useful tools for
cardiovascular research. They respond to pharmacological and physiological treatments
similar to adult cardiomyocytes, and are widely used for gene and protein expression,
histological, and contractility experiments1.
Adult cardiomyocytes represent mature, differentiated heart cells that must undergo
elaborate cytoskeletal adjustments in culture7. This makes them less flexible in cell
culture, but without the complication of potential mitotic activity. Isolated adult
cardiomyocytes are commonly used to model cardiac ischemia and hypoxia, as well as
contractile mechanics, gene and protein expression, and electrophysiology3. These cells
also have the advantage of representing the in vivo cardiac model closer than neonatal
cardiomyocytes, as in vivo rat experiments are usually performed on adults.

1.2.2

Animal models

The ideal animal model for cardiovascular research is one that closely mimics the
anatomy and physiology of the human heart and responds to stimuli similar to humans5.
Factors such as phylogenetics, size, life span, cost, and development of end-stage
diseases are all important when choosing an animal model for cardiovascular research.
The use of large animals presents several advantages and disadvantages. Large animal
models are physically, and in some cases phylogenetically, closer to humans than small
animal models, making studies more physiologically relevant4,6. Larger animals are often
easier to perform surgical procedures and imaging assessments, 11 however, their longer
life span and high cost of maintenance makes them very expensive and time consuming
to use4.
Small animal models are popular for cardiovascular research primarily because they are
inexpensive, convenient to house and maintain, have a relatively short gestation period,
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and therefore can produce large sample sizes over a short period of time11,12. The rat, in
particular, is one of the most popular models as its size compared to mice makes it easier
to perform open-chest surgical procedures such as coronary ligation, as well as MRI and
echocardiography imaging and the use of conductance catheters12. However, with the
development of transgenic and knock-out mouse strains, the murine model is often used
to investigate novel targets for pharmacological and molecular therapy12. Blood pressure
monitoring is feasible in rats and mice using the tail-cuff method, whether other rodent
models without a long tail, such as the guinea pig, are more difficult to use for these types
of measurements.

1.3

Overview of cardiovascular disease

Cardiovascular disease (CVD) is defined as a group of disorders of the heart and the
blood vessels that supply the heart, brain, and extremities13. CVD is accompanied by a
myriad of symptoms and dysfunctions, from hypertension to cardiomyopathy. Its
prevalence is increasing across the globe13, representing an immense burden to health
care systems. In Canada, CVD is the leading cause of hospitalization and accounts for 29
per cent of all deaths per year14. Treating CVD costs the Canadian economy $21 billion
per annum15. The steady increase in CVD cases internationally is largely attributed to an
imbalanced or poor diet and sedentary lifestyle13. Overnutrition and lack of regular
physical activity leading to obesity have negative consequences for the heart13. While
widespread campaigns for awareness and the promotion of improved diet and lifestyle
habits are among the principal strategies for reducing this trend, from a clinical
perspective, innovative approaches are needed to help prevent, intervene, and manage
CVD. Heart failure (HF) is defined as “the inability of the heart to pump a sufficient
amount of blood to meet the demands of the body at normal filling pressures”16. HF is a
complex syndrome and in many cases is considered the final outcome of several
manifestations of CVD. Myocardial infarction (MI) or heart attack, coronary heart
disease, hypertension and chronic inflammation, are all examples of confounding factors
that instigate and perpetuate HF.

7

1.3.1

Risk factors and prevalence of heart failure

The rate of mortality from CVD has decreased over recent years, due to improved acute
medical care, primarily rapid reperfusion17. However, the irreversible damage to the heart
associated with coronary heart disease and MI resulting in death of tissue, places patients
at high risk for HF. As a result, there are a growing number of patients surviving MI but
at high risk of HF. The prevalence of HF increases with age: 1 percent of Canadians over
65 and 4 percent of Canadians over 70 have HF16. With the ageing trend of the Canadian
population, HF will impact the lives of many people in the years to come. Currently in
Canada, 55,000 individuals are diagnosed with HF yearly, joining the half million already
living with the condition16. Once HF has manifested, the prognosis is bleak: 50 percent of
patients will die within the first five years of diagnosis18. One explanation is that a
portion of patients do not visit the doctor until the pathologies become symptomatic and
affect their everyday life. By then, the disease has progressed into later stages of HF with
irreversible damage. Research into mechanisms for reversing the many features of HF is
of great interest, as the standard treatments today are generally unable to rescue the
damage caused by MI and HF, and instead are targeted at reducing co-morbidities of HF,
including hypertension and arrhythmia. For these reasons, novel approaches to preventing
HF are desired.

1.3.2

Symptoms and the diagnosis of heart failure

The pathologies of heart failure can be acute, but by-and-large they manifest as a chronic
deterioration of heart function19. Several criteria and classification systems are
recognized for diagnosing HF19. The New York Heart Association (NYHA) classification
is the most commonly used system based on self-reports of patient’s daily activities and
quality of life20. Physicians classify patients with heart failure into 4 categories (I-IV),
from stage I representing mild, asymptomatic HF without any limitations on physical
activity, to stage IV representing severe HF with the inability to perform any physical
exercise without significant discomfort20. While this diagnostic system is popular, it is
limited to ability of the patient to recognize a symptom and consult a physician. Patients
in stage I and II HF do not experience symptoms severe enough to motivate a visit to the
doctor. Meanwhile, cardiac dysfunction progresses in the absence of intervention. Other
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classification and diagnosis systems require physical exams detecting evidence of cardiac
dysfunction based on chest radiographs19. While these methods have proven to be
sensitive and predictive, they require the patient to experience symptoms and discomfort
and then consult with a physician. Efforts to improve the early detection and treatment of
HF in Canada rely on disease management programs (DMPs), comprising intensive
therapy that includes drugs, education, monitoring, and caregiver assignment16. Patients
in the emergent and urgent categories of HF are primary candidates for DMPs and are
targeted to undergo evaluation within 24 hours to 2 weeks of the presentation of risks or
signs and symptoms. These categories include post-heart transplant, post-MI, and
myocarditis patients. Timely intervention for HF in the emerging and urgent categories
has resulted in a 30% reduction in death and re-hospitalization rates after 18 months of
follow-up and disease management16. This emphasizes the imperative to provide timely
access to intervention and treatment in high-risk HF patients, ultimately reducing
mortality and the costs associated with HF.

1.3.3

Hallmark features, treatments, and outcomes of heart failure

HF as a disease has several features, all in which result in the impaired ability of the
ventricles to fill and/or eject blood. Heart failure occurs most commonly in patients with
previous MI21. In the event of MI, the blocked blood flow from the coronary arteries to
the myocardium leads to necrosis and ischemia of cardiomyocytes22. Treatment strategies
for MI involve the prompt restoration of blood flow, using thrombolytic drugs, stents and
catheters, or bypass surgery, all in an effort to reduce the infarct size. Any duration spent
with blocked blood flow to the myocardium, will inevitably cause oxidative stress,
ischemia, necrosis and infarction. As a result, the heart undergoes a healing process in
efforts to recover from the damage sustained. While the process of post-MI repair and
remodeling is not entirely understood, there are highly regulated events involved that
become pathological in HF23.

1.3.4

The immune response

The degradation by matrix metalloproteinases (MMPs) of the existing extracellular
matrix (ECM) and coronary vasculature in the infarction region occurs within the one
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week post-MI21. Remodeling of the ECM is shown to play a significant role in several
vascular disorders, and MMP expression increases in HF23. With the production of
reactive oxygen species (ROS), necrosis, and ECM degradation, there follows an immune
reaction22. Pro-inflammatory cytokines and chemokines are released and macrophages
are recruited to clear debris, and promote cardiac healing and scar formation around the
damaged tissue24. However, chronic inflammation and macrophage recruitment can lead
to additional cell death and perpetuate the myocardial remodeling process. Some
important pro-inflammatory cytokines implicated in the progression of HF include
tumour necrosis factor (TNF)-α, interleukin (IL)-1 and IL-6, macrophage inflammatory
protein (MIP)-2, monocyte chemoattractant protein (MCP)-124,25. These cytokines
exacerbate myocardial and hemodynamic dysfunction and are typically up-regulated in
chronic HF. While the repair and healing process involving these agents are necessary
post-MI, there is a fine balance between promoting and preventing inflammation. IL-10 is
an important anti-inflammatory cytokine known to down-regulate the production of TNFα, IL-1, and IL-625. The antagonistic role of IL-10 is thought to be beneficial in HF
patients. Increased expression and plasma concentration of IL-10 has been shown to
improve cardiac mechanical function in rats and patients with HF25,26. However, the
protective nature of IL-10 is disputed as HF patients show varying levels of increased or
decreased plasma IL-1025. Overall, evidence suggests that the short-term and initial proinflammatory response becomes maladaptive in HF over time. Thus, anti-inflammatory
mediators such as IL-10 play an important role in the immune response to MI and HF,
and use of such mediators is being considered as a therapy27. It remains to be seen if these
will be successful. In inflammatory bowel disease, administration of anti-TNF-α
antibodies (Infliximab) has shown some benefits28, while administration of IL-10 by a
genetically engineered food-grade bacterium, Lactococcus lactis, has some pre-clinical
evidence but awaits confirmation in patients with colonic inflammation29.

1.3.5

Ventricular remodeling and hypertrophy

Following the immediate inflammatory reaction post-MI, a regulated process of cardiac
remodeling takes place. Ventricular remodeling is defined as genome expression
resulting in molecular, cellular, and interstitial changes30. Clinically, this process is
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manifested as changes in size, shape, and function of the heart, and is considered a
determinant of heart failure30. MI stands as the most common instigator of cardiac
remodeling, and the changes also occur in patients with other cardiac pathologies such as
stenosis, hypertension, and myocarditis30. In post-MI patients, within the first week of
ECM degradation by MMPs, phagocytic macrophages are recruited to the infarct site for
digestion and removal of infarcted tissue21. Fibrogenic mediators, such as transforming
growth factor (TGF)-β, then increase the synthesis of collagen by myofibroblasts to
replace the degraded ECM and form scar tissue21,31. Scar tissue formation is evident
around week 2 post-MI and continues for over 8 weeks21. This process of wound healing
provides some potential for the infarct site to function again as the contractile properties
of myofibroblasts generate small and strong scars with the potential to bear load31.
However, the inevitable build-up of collagen in the infarct area and beyond also causes
ventricular stiffness and dysfunction31.
The loss of functional myocardium causes an increase in blood volume in the ventricle
that is not properly cleared with contraction. The increased load and ventricular wall
stress is sensed by cardiomyocytes which undergo compensatory changes to the cellular
architecture of the ventricle. Because cardiomyocytes are terminally differentiated and
cannot divide, they instead respond to wall stress by cell stretching/lengthening to
increase wall thickness32-34. This abnormal growth of cardiomyocytes, termed cardiac
hypertrophy, is a hallmark feature of HF35-37. Hypertrophy is an adaptive response that
initially increases the mass of the functional myocardium, distributes wall stress, and
normalizes resting cardiac output36,38. Chronically, this response becomes maladaptive,
due to poor contractility of hypertrophic cardiomyocytes, which leads to a decrease in
cardiac output, increased rate of apoptosis and fibrosis, and increased risk for cardiac
arrhythmias35,36. For these reasons, cardiac hypertrophy is a very important therapeutic
target for heart failure patients. Modern treatments of heart failure, including β-blockers
and angiotensin converting enzyme (ACE)-inhibitors have been shown to improve
hypertrophy by reducing the heart rate and hemodynamic load, which reduces the stress
stimulus for cardiomyocyte growth37. More targeted approaches to attenuating
maladaptive hypertrophy are desired.
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1.3.6

The hormone response

Post-MI, a hormone-mediated recovery process takes place in an effort to maintain
mechanical function of the heart. These hormones are often considered biomarkers of HF
and represent the compensatory response. Atrial natriuretic peptide (ANP) is a hormone
secreted primarily by the atria that has diuretic, natriuretic, and vasodilator properties39,40.
Ventricular expression of ANP can be induced in conditions of hypertension, wall stress
and ventricular load, and increased ventricular mass39,40. ANP production is strongly
correlated to cardiomyocyte size, where a higher incidence of ANP expressing
cardiomyocytes is found in cells with larger diameters41,42. Increased levels of ventricular
ANP expression in animal and cell models of cardiac hypertrophy and HF have been
thoroughly documented41,43,44. In these conditions, it is thought that ANP acts to reduce
cardiac load and wall stress through its anti-hypertensive properties42. Accordingly,
ventricular ANP expression is strongly correlated with cardiac hypertrophy and is used
extensively in vitro and in vivo as an indicator of hypertrophy and HF39,41.
In HF, contractile dysfunction leads to a decrease in cardiac output45 which then
determines arterial circulation. This is sensed by β-adrenergic receptors in the ventricle
walls which drive sympathetic nervous system output to increase contractility, cardiac
load, and heart rate30. Decreased cardiac output also triggers the renin-angiotensinaldosterone system. These renal hormones promote water retention, vasoconstriction and
increase blood pressure to maintain blood flow to vital organs. To the heart, activation of
this system has deleterious effects and exacerbate pre-existing co-morbidities of HF such
as hypertension. Angiotensin II, a potent vasoconstrictor, autocrine and endocrine
hormone produced by heart cells, induces cardiac hypertrophy through its hypertensive
properties36,46. Cardiomyocytes enlarge due to the increased vascular resistance of blood
flow and, as a consequence, ventricular ANP production is activated32,46. It has also been
suggested that angiotensin II activity via the β-adrenergic pathway causes cardiac
hypertrophy independent of hypertension45-47. For these reasons, drugs blocking the
action of the hormones in the renin-angiotensin-aldosterone system have become some of
the most effective therapies for HF45,48-50. ACE-inhibitors reduce the activity of the reninangiotensin-aldosterone system by preventing the conversion of angiotensin I to
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angiotensin II. As a result, vasoconstrictive and hypertrophic action of angiotensin II is
reduced. Short-term β-adrenergic blockage also improves ventricular function and
decreases morbidity and mortality in patients with HF51. β-blockers overall have
improved survival in post-MI and chronic HF patients, and in combination with ACEinhibitors are considered the first-line drug therapy for HF patients33,49,50.
Hormones that are unrelated to hemodynamic regulation are also involved in HF. Leptin
is a hormone chiefly secreted by adipocytes that plays an important role in energy
balance, appetite, and metabolism. Leptin has been associated with several mechanisms
of pathogenesis in obesity and type II diabetes, both of which are risk factors for HF52,53.
Furthermore, elevated plasma leptin levels are associated with increased risk coronary
heart disease (CHD) and hypertension, independent of obesity and diabetes53,54. As such,
leptin is a proposed biomarker and independent risk factor for myocardial infarction,
ischemic heart diseases, CHD and HF52,55-57. While adipocytes are the major source of
leptin, evidenced by high plasma leptin levels in individuals with increased adiposity58,
the heart has shown to both secrete and express receptors for leptin56. The cardiovascular
actions of leptin are in part based on the stimulation of the sympathetic nervous system
that is thought to cause a hypertensive effect54,55. The stimulation of the β-adrenergic
pathway by leptin receptors in the heart upregulates angiotensin II expression, which in
turn stimulates increased leptin secretion by adipocytes52. Leptin can also potentiate
secretion of pro-inflammatory cytokines such as TNF-α, IL-2, and IL-652, all of which are
upregulated in HF, as previously discussed. Leptin is has been shown to promote
atherogenesis, cardiac hypertrophy, and is elevated in post-MI and HF patients52,57,59,60.
Overall, leptin participates in a viscous cycle of inflammation and β-adrenergic
activation, causing cardiac pathologies that are deleterious to HF patients.

1.4

The human microbiome: a dynamic ecosystem

The human body is host to dynamic microbial communities that have an increasingly
recognized impact on human health. The gut, skin, vagina, urinary tract and oral cavity
are among sites where microbial communities exist in an equilibrium that is required for
proper function and health61. As a whole, the genomes, activity, size, compositions and
surrounding ecosystems of these communities represent the human microbiome61.
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Formerly, the organisms in body sites were investigated using traditional laboratory
cultivation techniques. This limited the identification and enumeration of the
communities due to the inability to cultivate many species. With the advancement of
culture-independent techniques, the composition of the human microbiome and the role it
plays in our health, have become better understood. Recent research, notably championed
by the Human Microbiome Project (HMP) consortium62, has attempted to characterize
“normal” microbiota composition of various sites throughout the body63-65. Using highthroughput next-generation DNA sequencing of the 16S rRNA genome, the analysis of
over 4000 specimens collected from 242 adults revealed that each site has a characteristic
microbiome, with constituents adapted to specific niches61,63,64. The gut, for example, is
generally dominated by two phyla: Firmicutes and Bacteriodetes, while other phyla,
including Proteobacteria and Actinobacteria, exist in smaller proportions66,67. The gut
bacteria perform a multitude of functions from the transformation of bile acids,
breakdown of insoluble fibers, to the production of specific vitamins and cofactors68.
Despite individuals having somewhat unique microbiota patterns in the gut, many
functions appear to be shared. Even with large numbers of organisms (greater than 1014)
present, the addition of organisms in comparatively low numbers (109 or less) such as in
the form of probiotics or alternatively pathogens, can still significantly affect the host
through their production of metabolic by-products- toxins as in the case of the latter69,70,
bacteriocins, modulation of other host factors such as the immune system71-73

1.4.1

Microbial dysbiosis: Etiology for disease?

The critical role of the microbiome in host health is illustrated by the fact that a shift to
dysbiosis is now associated to several gastrointestinal diseases including inflammatory
bowel disease, C. difficile associated diarrhea, colon cancer and other forms of enteritis7476

. In the oral cavity, a disruption of the homeostatic function of commensal bacteria

caused by the colonization of a single pathogenic species can lead to periodontitis and
other gingival diseases77,78. In the vagina, a displacement of commensal Lactobacillus
species by various anaerobes is characteristic of bacterial vaginosis, a condition that
causes an increased risk of endometriosis, pregnancy complications, and pre-term
labour79-81.
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While the incidence of microbial-associated disease at the primary site of colonization is
intuitive, the impact of dysbiosis is much more far-reaching. There is mounting evidence
that bacteria in the gut can influence distal sites, and for example contribute to the
development of metabolic syndrome82,83. In addition, individuals with type II diabetes
and obesity have a gut microbial composition of less diversity compared to that of
healthy individuals84 and the balance of Firmicutes and Bacteriodetes shifts to one with a
dominance of the former84-86. Studies also demonstrate a link between the brain and gut
microbiota associated with a variety of neurological conditions, including appetite
disorders, multiple sclerosis, hepatic encephalopathy, and Autism Spectrum Disorder
(ASD)87-91. Several mouse models have demonstrated that the gut microbiota can convey
neurological signals via vagus nerve stimulation, immune-modulatory signaling, and
neuroendocrine pathway signalling92,93. Furthermore, is has been anecdotally reported
that antibiotic and probiotic use, presumably altering the gut microbiome, causes
behavioral changes and clinical improvements in children with ASD94,95. Although the
mechanisms for these relationships are not entirely elucidated, it is clear that microbes in
one site can influence overall health status.

1.4.2

The oral microbiome and CVD

The oral microbiome comprises a population that can withstand exposure to the external
environment and a diverse range of conditions. With over 700 species of bacteria
identified in the oral cavity, and diverse surfaces in which the organisms can colonize,
from the hard teeth to the deep gingival tissue pockets, the options for propagating are
many, and the result is distinct patterns in the different niches96. The oral microbiome
plays an important role in the health status of the host, and a shift in microbial
composition can cause numerous local infections including periodontitis, caries,
gingivitis, and tonsillitis96-98. In addition, it has been implicated in several systemic
diseases, including CVD. There is a strong clinical association with chronic periodontal
disease and increased risk for atherosclerosis, hyperlipidaemia, CHD, stroke, and MI98101

.

Periodontitis is a severe infection that attacks both the soft tissue and bone supporting the
teeth101. Opportunistic oral pathogens overgrow in periodontal pockets and release
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proteolytic enzymes that break down host tissue101. These pathogens are extremely
difficult to eradicate and the disease often manifests over chronic periods of time.
Pathogens implicated in periodontitis are often detected in blood cultures, as they are able
to enter systemic circulation via the compromised oral mucous membrane102,103. The
access to organs throughout the body represents a major risk for inflammation and
infection. It is the chronic nature, however, of periodontitis that is thought to increase the
risk for CVD104. Cross-sectional studies suggest that the inflammatory factors associated
with periodontitis, such as C-reactive protein, plasma fibrinogen, IL-6, and
hyperlipidaemia, are responsible for the increased risk of CVD98,101,104,105. Cohort studies
have found positive dose-dependent associations between chronic periodontitis and the
incidence of CHD in men less than 60 years old, independent of pre-existing CVD risk
factors (including old age)103,105,106. While these associations have been documented for
well over 25 years, there is significant variability among studies and subjects104. The
advent of deep genome sequencing has led to an increased effort to track shifts in the
microbial community between health and disease. Changes in the oral microbiota occur
in response to treatment for periodontal disease, with several genera of periodontal
pathogens depleted in patients who had undergone treatment107. This line of research may
shed light on the mechanistic role of periodontal pathogens in CVD, by comparing the
plaque microbiota of periodontal patients at risk for CVD with healthy, matched controls.

1.4.3

Gut microbiota, diet, CVD

In the so-called ‘Western world’, the prevalence of CVD coincides with other chronic
conditions such as obesity, type II diabetes, and gut inflammation. Metabolic disease,
which includes hypercholesterolemia, diabetes, and obesity, is largely diet-dependent and
is a key preventable risk factor for CVD. It has been well documented that individuals
with obesity have a gut microbiome profile distinct from those of lean subjects66,86,108,109.
In diet-induced obesity, overnutrition can alter composition of the gut microbiome, with
dietary nutrients influencing the growth of certain species. Diets rich in cholesterol,
saturated fats, and simple carbohydrates are associated with gut microbiomes rich in the
Firmicutes phylum67,110. In obese individuals, the decreased proportion of Bacteriodetes
in comparison to Firmicutes is normalized with a low-calorie diet-associated weight
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loss67. Conceivably, these obesity-associated microbiome profiles feature organisms that
are more adept at processing the energy-rich diets. This theory is supported by
metagenomic and biochemical analyses showing that the core gut microbiome of obese
individuals has an increased capacity for energy harvesting, compared to lean
individuals111. This capacity was characterized by the genomic expression of KEGG
pathways associated with starch/sucrose metabolism, galactose metabolism, and
butanoate metabolism111. When the gut microbiota from normal mice is transplanted into
germ-free recipients, there is an increase in weight and adiposity without any increase in
food consumption67. This indicates that the increased energy harvesting capacity is
transmissible. The modern Western diet, high in refined sugars and lipids but lacking
complex fermentable fibers, is seemingly mismatched with the capacity of our ancestral
microbiota. This consequently results in less diversity and a shifted microbiome
profile110. It has been suggested that a return to ancestral diets, consisting mainly of plantbased complex fibers and low in red meat, can help promote the proliferation of the
beneficial microbes considered indigenous to our gut112.
Epidemiological studies indicate that vegetarians and vegans have lower blood
cholesterol and lower risk for CVD compared to omnivores112,113. The elimination of red
meat from the diet can be beneficial for cardiovascular health114,115. It has been reported
recently that gut microbes play a significant role in the metabolic processing of red meat.
Dietary carnitine and phosphotidyl choline, predominantly from red meat, is converted to
trimethylamine (TMA) by gut microbes116. TMA is then converted to the proatherogenic
metabolite trimethylamine-N-oxide (TMAO), which accelerates atherosclerosis in
mice116. The conversion of dietary carnitine to TMAO is gut microbe dependent, as
individuals receiving oral antibiotics for a week prior to consuming red meat experienced
a complete suppression of endogenous TMAO production116. The same study also
reported that vegetarians and vegans had significantly lower fasting baseline TMAO
levels, compared to omnivores116. Correspondingly, vegetarian and vegans had
significantly higher abundance of Bacteriodes and lower abundance of Prevotella species
in the gut microbiome than omnivores, and a decreased risk for coronary heart disease
and the traditional risk factors for CVD such as hypertension, atherosclerosis, peripheral
artery disease, and stenosis116. As vegetarian and vegan diets typically consist of very
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high portions of plant fibres, fermentable substrates and low dietary carnitine, all of
which are metabolized by gut microbes, this provides strong evidence for a role of the
microbiota in CVD.
In terms of prevention and treatment strategies, these findings data are extraordinarily
valuable. The increased adiposity, angiogenesis, blood flow, and cardiac output
associated with overnutrition and obesity is a major risk factor for hypertension and
hyperlipidemia; major risk factors for atherosclerosis, MI and coronary heart disease, all
of which predispose to congestive HF117. If modulation of the gut microbiome can
interrupt this progression at any point, there is a potential to improve an individual’s
cardiovascular health. Developing the most efficacious method of manipulating a
dysbiotic microbiota with no detriment to the host, represents a novel area of
investigation for diseases like CVD.

1.5

Modulation of the human microbiome

As our understanding of the elaborate relationship between the human microbiome and
the host expands, strategies for modulating the microbiome have evolved. Modern
medicine has relied heavily on the prescription of antibiotics in efforts to eradicate
infectious pathogens. Some episodes induced by C. difficile, E. coli, Salmonella spp., and
H. pylori can be controlled with the use of antibiotics118, however not without significant
detriment to the host. Antibiotics are relatively non-discriminating agents, unable to
distinguish between pathogenic and non-pathogenic bacteria. As a result, antibiotic use
disrupts the microbiome and eliminates endogenous bacteria that perform vital functions
for our health. Antibiotic-associated diarrhea occurs in at least 20% of antibiotic users,
due to the decreased fermentation capacity and malabsorption in the gut119,120. Antibiotic
use can lead to secondary infections, when opportunistic pathogens normally suppressed
by endogenous microbes are able to proliferate. For these reasons, the widespread
prescription of antibiotics has been discouraged, and alternative methods are being
explored.
Probiotic therapy is one such method that has gained increasing attention among
consumers, health practitioners, and researchers. The accumulating reports of the health
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benefits of probiotic products in the laboratory and the clinical setting have catapulted
novel strategies for probiotic use for diseases to the gastrointestinal system and beyond.

1.5.1 Probiotics to restore homeostasis
The consumption of bacteria is not a modern trend; ancient diets featured fermented food
products from various grains, vegetables, beans, fish, and dairy products. In fact, it was
the observation of the overall good health and longevity of certain ethnic Europeans
consuming fermented foods that brought modern-day prominence to probiotics121. Today,
the United Nations and World Health Organization and many other organizations define
probiotics as live microorganisms which when administered in adequate amounts confer
a health benefit on the host79.
Despite most regulatory authorities not allowing disease claims for foods without
pharmaceutical level supporting studies, there is strong clinical evidence supporting
probiotic foods and supplements treating bacterial vaginosis122, diarrhea123,124, and
irritable bowel syndrome124-128, as well as improving the management of Helicobacter
pylori129 and Clostridium dificile-associated diarrhea130. In most cases, the effects are
strain specific and the precise mechanisms for the action not well elucidated. There are
several ways in which probiotics interact with the host. First, the introduction of a
probiotic species into a bacteria-harboring environment can alter the existing community
dynamic. Probiotics have demonstrated competition against pathogens and deleterious
organisms, interfering with their ability to infect the host131,132. Various mechanisms
have been studied including production of bacteriocins, biosurfactants and simple
competitive exclusion72,133,134. The net effect of suppressing pathogenic activity can be
restoration to a 'healthy' equilibrium of the microbial community. Second, probiotics
participate in epithelial cross talk with the host immune system135. The gut epithelium is a
major barrier against foreign pathogens and antigens. Probiotics not only improve the
integrity of the epithelial barrier136, but also interact with toll-like receptors and
transcription factors that regulate inflammatory responses137,138. This immune-modulating
effect has proven beneficial not only for local gastrointestinal diseases such as
inflammatory bowel disease and necrotizing enterocolitis135,137, but also distal conditions
such as rheumatoid arthritis139. Third, probiotics are producers of many metabolites,
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enzymes, co-factors and vitamins that are active in modulating our health. For example,
the fermentation of carbohydrates by probiotics results in the production of short chain
fatty acids, such as acetate or propionate, which are used as energy sources by the host68.
Certain probiotic strains produce vitamin K, B2, B12, and folate140-143, which are utilized
by the host.

1.6
Probiotics: Evidence for reducing risk factors for
CVD
1.6.1 Via interference with periodontal disease
The use of probiotics in the oral cavity has been investigated for reducing pathogenic
agents in several types of oral disease. For example, L. rhamnosus and L. reuteri strains
have shown to reduce the number of S. mutans, a caries pathogen, when consumed in
yogurt or milk144,145. Similarly, the consumption of probiotic cheese and S. salivarius
reduced the prevalence of oral Candida in an elderly population146. Streptococcus
salivarius K12 is a probiotic strain shown to release large amounts of bacteriocins into
the saliva that compete with pathogenic microbes147. The strain is commercially available
in lozenge and chewing gum forms and has been shown to reduce oral candidiasis in a
mouse model148, malodor in patient with halitosis149, and inhibit baseline secretion of IL8 while activating the anti-inflammatory pathway of nuclear factor (NF)-κB in human
bronchial cells challenged with Pseudomonas aeruginosa150.
Although periodontitis is a very difficult disease to cure, there is encouraging evidence
that probiotics can contribute through reduction of periodontal pathogens and
inflammation. In two independent clinical studies, L. reuteri significantly reduced several
clinical indices of periodontal disease, including gingival bleeding, plaque, and microbial
levels of periodontal pathogens151,152. Similar results have been reported using other
lactobacilli and Bifidobacterium products, where normalization of the oral microbiota
occurred with treatment of gingivitis and periodontitis patients153,154. L. reuteri also
reduces the pro-inflammatory cytokines TNF-α and IL-8 in patients with gingival
inflammation, when taken in a chewing gum for two weeks155. These studies provide
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strong support for the use of probiotics as a therapy for oral diseases, yet mechanistically
speaking, the data are incomplete.
The ability of probiotic organisms to attach and colonize the oral cavity are believed to be
important, but long-term colonization is rare156. There are conflicting reports on the
persistence of probiotic strains in the oral cavity once treatment has been removed and it
does not seem that colonization is a prerequisite for effective treatment in some cases157.
Since periodontal disease is a contributing factor in CVD, the ability of probiotics to
alleviate the former could influence the latter, although no studies with this specific aim
have been performed.

1.6.2 Obesity and adiposity
The increased risk and prevalence of CVD can largely be attributed to diet and lifestylederived disorders. Obesity is one of the primary risk factors for CVD, as the progression
from overweight to obese introduces a slew of comorbidities that are detrimental to
cardiovascular health158. The excessive energy intake and fat accumulation in obesity
presents major risk for type II diabetes, chronic inflammation, and hyperlipidemia, all of
which predispose to coronary heart disease, cardiac arrest, and HF158. The accumulating
in vitro, animal, and human research suggests an opportunity for probiotics to improve
these risks. It has been established that obese individuals have a different gut microbiome
profile from normal weight individuals67,85,86,108, indicating a partial role of the
microbiome in obesity. The use of probiotics to re-set the dysbiotic obese gut microbiome
is one proposed mechanism of action. A study performed on healthy weight mice found
that there were significant changes in the gut microbiome as well as significant weight
reduction in mice receiving either L. rhamnosus GG or L. sakei NR28 daily by oral
gavage for 3 weeks159. Overall, both probiotic treatments resulted in a reduction of the
total number of microorganisms in the gut, and the Firmicutes/Bacteriodetes ratio was
significantly reduced159. This change in ratio was seemingly due to a reduction in
Clostridium species belonging to the Firmicutes phylum, rather than an increase in
Bacteriodetes organisms. There was no significant difference in food consumption
between control and probiotic treatment groups, indicating that the significant reduction
in epididymal fat mass was not due to a reduction of energy consumption159. Results from
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this study indicate that the modulation of the gut microbiome with probiotic
administration produces an anti-obesity effect that directly reduces epididymal fat mass.
However, efforts to significantly alter the human gut microbiota using probiotics have
shown less subtle effects160.
In humans, the twice daily administration of a multi-strain probiotic capsule
(Streptococcus thermophilus, Lactobacillus plantarum, Lactobacillus
acidophilus, Lactobacillus rhamnosus, Bifidobacterium lactis, Bifidobacterium longum,
and Bifidobacterium breve) to overweight individuals with a body mass index greater
than 25 resulted in a significant reduction in weight, waist circumference, and serum
cholesterol after 8 weeks161. These metabolic changes positively correlated with a
significant increase in Lactobacillus plantarum populations and the overall ratio of gram
negative bacteria, presumably representing the Bacteriodetes phylum161. Probioticinduced changes to the gut microbiome composition is not an exclusive prerequisite for
weight and adiposity reduction. There are numerous reports of improved body fat mass
and weight loss without any differences in gut microbial composition, suggesting and
explicit relationship between probiotic and adipose tissue. Certain metabolites have been
implicated to directly reduce adipose tissue mass. Conjugated linoleic acid (CLA)
produced by certain Lactobacillus species have shown to reduce obesity and
arteriosclerosis in mice108,162. Studies investigating CLA-producing probiotic strains have
demonstrated that Lactobacillus rhamnosus PL60 and Lactobacillus plantarum PL62
reduce body weight and adipose tissue mass in mice on a high fat diet in a CLAdependent manner, without any changes in food intake163,164. Probiotics have directly
reduced adipocyte cell size in high fat diet mice165,166, which can improve oxidative stress
and the subsequent chronic inflammation associated with inadequate blood supply to
enlarged adipocytes in obesity.

1.6.3 Cholesterol and hypertension
One of the most thoroughly investigated applications of probiotic therapy for CVD is for
reduction of serum cholesterol. Elevated low-density lipoprotein cholesterol (LDL-C) is a
major risk factor for CVD167. The accumulation of LDL-C in the blood is a precursor to
hypertension, hyperlipidaemia, and causes the formation and build-up of atherosclerotic
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plaque in the arteries167. Meta-analyses of randomized controlled clinical trials have been
performed to evaluate the effect of probiotic consumption on serum LDL-C and total
cholesterol levels. Pooled data from a total 485 total participants with 'high' 'borderline
high' and 'normal' serum cholesterol levels found that probiotic consumption significantly
lowered LDL-C and total cholesterol levels among all categories, compared to the
control168. The cholesterol-lowering properties of probiotics are strain and species
specific; and among these select probiotics, there are several postulated mechanisms of
action. Probiotics can remove cholesterol from the gut by incorporating cholesterol in to
the cellular membrane during growth and proliferation. In vitro studies using
fluorescently tagged cholesterol molecules have tracked the incorporation into the
cellular membrane by several strains of lactococci and lactobacilli169,170. Cholesterol can
also be converted to coprostanol by probiotics expressing cholesterol reductase170.
Coprostanol is subsequently excreted in feces, potentially reducing cholesterol absorption
in the gut.
Perhaps the most accepted mechanism is the processing of bile acids in the gut by Grampositive organisms including Lactobacillus, Bifidobacterium, and Bacteriodetes171.
Metabolism of cholesterol, a precursor of bile acids, is mediated through gut microbes
expressing the enzyme bile salt hydrolase (BSH). Probiotic strains with high BSH
activity promote the deconjugation of bile acids to secondary amino acid conjugates172.
When these are then excreted, and cholesterol is broken down to replace the processed
bile salts. Overall, this process promotes the catabolism of cholesterol and reduces serum
cholesterol levels171. There is considerable variability in BSH activity among probiotic
species, indicating that genes, which encode it, are likely to be horizontally acquired173. It
is also known that many probiotic strains express more than one BSH homologue171. This
might maximize survival because of the variable exposure to different forms of bile salt
conjugation in the gut. Further research is required to precisely identify the mechanism of
the BSH gene and activity, especially with regards to the kinetics of bile salt transport.
Most of the above mechanisms have been exclusively explored in vitro, and more animal
and human trials are required. However, regardless of the mechanism implied, the
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extensive meta-analyses on human clinical trials indicate that the use of probiotics to
lower serum cholesterol is a promising prevention strategy for CVD.
Hypertension, closely tied to hypercholesterolemia, is a major risk factor for CVD174.
About 30% of Americans are hypertensive, doubling their risk for developing the
disease174. Reducing hypertension alone, using diuretics, ACE-inhibitors and β-blockers
is about 30% less effective than reducing hypertension by treating hypercholesterolemia
in hypertensive patients174. This suggests that not only does probiotic therapy improve
lipid blood chemistry, but it also can improve hypertension and outcomes for CVD
patients. Meta-analysis of fourteen randomized placebo-controlled clinical trials with 702
participants showed that probiotic fermented milk significantly reduced both systolic and
diastolic blood pressure in pre-hypertensive and hypertensive patients175. Certain
probiotic strains produce peptides with ACE-inhibitory activity through the proteolysis
and fermentation of milk proteins176,177. When growth of certain Lactobacillus and
Bifidobacterium strains was enhanced using fermentation substrates, or prebiotics (inulin,
pectin, fructo-oligosaccharides, and mannitol), proteolytic activity and ACE inhibition
was proportionally increased177. Further research on maximizing the production and
evaluating the activity of these peptides in vivo is required.
By reducing cholesterol and hypertension, two of the most prevalent risk factors for
CVD, the risk for developing coronary heart disease, atherosclerosis, heart attack, and
stroke is reduced by nearly half174. The strong clinical evidence for the attenuation of
hypercholesterolemia and hypertension with probiotic consumption brings encouraging
support for the treatment of CVD with probiotics.

1.6.4 Direct cardioprotection against apoptosis and ischemic injury
Until recently, probiotic applications for cardiovascular health were limited to metabolic
and diet-associated processes. The aforementioned evidence for probiotic therapy for
CVD pertains mostly to symptoms of CVD that are precursory to direct heart damage
incurred by coronary artery disease, myocarditis, MI, and HF. We wanted to explore
whether probiotics can provide a direct, cardioprotective effect to the heart that results in
reduced ischemic injury and improved cardiac function, following an ischemic event. If
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coronary arteries become occluded, the blocked blood supply to the heart muscle can
cause tissue ischemia and infarction. If a patient survives MI, there is a risk for
progression to HF and chronic inflammation, as the damaged heart struggles to maintain
its regular work capacity. Reduction of ischemic injury and infarction is critical to
improving the outcomes of MI patients.
The protective role of probiotics against apoptotic injury was first investigated in
intestinal cells. While exploring the mechanisms of action against inflammatory bowel
disease, it was found the L. rhamnosus GG prevented TNF-α, IL-1α, and interferon
(IFN)-γ-induced apoptosis in mouse colon cells178. This was achieved through both
activation of the anti-apoptotic Akt pathway, and inhibition of the pro-apoptotic p38
mitogen-activated protein kinase pathway178. The purification of L. rhamnosus GG
supernatant identified a novel protein, p75, to be responsible136. The effect of this protein
on ischemia/reperfusion (I/R) induced heart cell injury was evaluated using a rat model.
The pre-treatment of rats with the purified p75 protein isolated from L. rhamnosus GG 30
minutes prior to I/R surgery significantly attenuated heart tissue infarction in a dosedependent manner. This phenotype was reportedly generated by enhanced expression of
heat shock proteins with p75 pretreatment179, suggesting that proteins produced by
Lactobacillus have a direct cardioprotective effect against ischemic injury. Further
mechanistic research is required, as the isolated p75 protein delivered in a bolus,
bypassed the gastrointestinal system. Studies examining the production and kinetics of
p75 from L. rhamnosus GG within the gut could contribute to an understanding of the
role of the microbiome in this phenotype.
Recently, a rat study demonstrated that oral consumption of a probiotic could be
cardioprotective. Animals administered the probiotic drink marketed as “GoodBelly”,
containing Lactobacillus plantarum 299v, in their drinking water for up to 14 days before
I/R heart surgery, had a 29% reduction in ischemia and a 23% improvement in postischemic mechanical function, as measured by left ventricular diastolic pressure180. This
cardioprotection seemed to be gut microbiome-dependent, as administration of
vancomycin generated the same phenotype. It was found that the attenuated ischemia was
independent of cytokine mediation, but dependent on serum leptin reduction. There was a
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significant increase in serum leptin post-I/R that was significantly attenuated with
GoodBelly and vancomycin pretreatment180. Pretreatment with leptin abolished the
cardioprotection confirming that this molecule played a key role in the process. Leptin is
a hormone mainly produced by adipocytes but also by cardiomyocytes, and is typically
upregulated in CVDs such as HF and hypertension. This novel finding linking
communication between the gut and heart through hormone signaling, warranted further
research into the cardioprotective properties of probiotics.
We decided to determine whether probiotic treatment post-ligation injury without
reperfusion could confer benefits reported with probiotic pre-treatment. In addition, we
wanted to further investigate the mechanisms by which probiotic activity worked.

1.7

Hypothesis and objectives

My hypothesis was that the administration of Lactobacillus probiotic strains will have a
beneficial effect on the outcome of myocardial infarction-induced heart failure and provide
a direct benefit to cardiac tissue through gut-bloodstream mediators.
Objective 1: Assess the effect of oral probiotic administration on the outcomes of gut
microbial composition and MI-induced heart failure in a rat coronary artery ligation
model.
My aim was to determine the effect of probiotic administration after the MI event. This
study assessed changes in the gut microbiota associated with probiotic administration.
Objective 2: Assess the effect of direct probiotic administration on cardiomyocytes
expressing the hypertrophic response associated with heart failure.
Using chemical agents to induce hypertrophy, my aim was to evaluate the effect of coculturing cardiomyocytes with probiotic lactobacilli. I examined both morphological and
molecular changes of cardiomyocytes in co-culture. Using a variety of tools for generating
different probiotic treatments, this in vitro model tested if probiotics directly interact with
and benefit cardiomyocytes and help elucidate potential mechanisms.
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Chapter 2 : Materials and Methods
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Overview of experiments

2

The experiments performed for this thesis can generally be divided into two groups: in
vivo animal studies, and mechanistic in vitro studies. The specific designs for all
experiments performed are described in detail in the next sections.

2.1
The effect of probiotic administration on the
outcome of heart failure in the rat
In collaboration with Dr. Morris Karmazyn (Department of Pharmacology and
Physiology, Western University), a study was designed to investigate the outcome of
probiotic therapy for heart failure in the rat. There were two stages: First, a 4 week pilot
study was performed on 15 animals using 2 different probiotic strains. This served as a
proof-of-concept assessment. Next, a 6 week comprehensive study using 60 animals and
only one probiotic treatment was performed. The methods described in this section have
been published and are described in detail below181.

2.1.1

Probiotic culture and treatment preparation

In the 4 week pilot study, two different probiotic strains were prepared as treatments:
Lactobacillus rhamnosus GR-1 or Lactobacillus plantarum 299v. L. plantarum 299v was
chosen because it was the probiotic strain in the commercially available drink
(GoodBelly, NextFoods, Boulder, CO, USA) that was demonstrated to have
cardioprotective effects against I/R injury to the heart180. L. rhamnosus GR-1 was chosen
because it has been extensively characterized by several laboratories and has been shown
benefit the gastrointestinal and urogenital tracts182,183. In addition, the genome sequence
for L. rhamnosus GR-1 was available within our group, which may have provided further
tools for analysis.
All media for bacterial culture were acquired from Becton and Dickinson (BD,
Mississauga, ON). All strains were grown under anaerobic conditions at 37°C, using the
GasPak™ system (BD). Details on each strain are provided in table 1.
L. plantarum 299v was isolated from a sample of GoodBelly by inoculating de Man,
Rogosa, Sharpe (MRS) broth with the drink using an inoculation loop. The broth was

28

grown for 15 hours then streaked onto MRS agar and grown again for another 15 hours.
After 3 subsequent sub-cultures were performed, 2-3 single isolated colonies were added
to MRS broth (20% glycerol) in a sterile cyrotube for long term storage at -80°C. Freezer
stocks of L. rhamnosus GR-1 were maintained in the same media at -80°C. The L.
plantarum 299v strain was identified by polymerase chain reaction (PCR) using an
Eppendorf Mastercycler® PCR machine (Eppendorf, Hamburg, Germany).
Frozen stocks of both L. plantarum 299v and L. rhamnosus GR-1 were resuscitated by
propagating in MRS broth, as described above. Isolated colonies were streaked onto MRS
agar to prepare a sub-culture. Single colonies were used to inoculate 3 ml of MRS broth,
and in turn used to inoculate 500 mL MRS broth. After growth, the cells were centrifuged
at 1600 x g for 20 minutes. The supernatant was completely removed, and the cells
washed twice with cold sterile phosphate buffered saline (PBS). The pellet was
resuspended in 25 mL 10% sterile skim milk (Nestlé, Markham, ON) to a concentration
of 3.0 x 1010 colony forming units (CFU)/mL. Aliquots of 100 µL of L. rhamnosus GR-1
in skim milk, or skim milk alone as a placebo control, were placed in sterile 1.5 mL
Eppendorf tubes to create individual daily treatments. These were stored at -20°C until
use.
Bacterial cell numbers were confirmed by serial dilution and bacteriological plate count.
In addition, aliquots were subjected to freeze-thaws to reconfirm the bacterial numbers
present and to ensure the placebo was not contaminated.
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Table 1. Probiotic strains and preferred growth media used in animal studies
Strain Source

L. plantarum

299v

GoodBelly

Non-selective

Selective growth

growth media

media

MRS broth/agar

LPSM

MRS broth/agar

MRS FA

probiotic drink
isolate
(NextFoods)
L. rhamnosus

GR-1

Distal urethral
clinical isolate

MRS: de Man, Rogosa, Sharpe Lactobacillus culture medium
LPSM: Lactobacillus plantarum selective medium184
MRS FA: de Man, Rogosa Sharpe Lactobacillus culture medium with the addition of 32
µg/mL fusidic acid (FA)
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2.1.2

Animals

The animal experiments were approved by the Animal Use Subcommittee of Western
University and a copy of the the Animal Use Protocol is provided in the appendix.
Procedures adhered to the guidelines of the Canadian Council on Animal Care (Ottawa,
ON). The experiments were performed on male Sprague-Dawley rats weighing between
175-225 grams (body weight was determined immediately prior to commencing the
study). Animals were randomly assigned treatment groups as outlined in table 2. Animals
were fed a standard chow diet throughout the studies.

2.1.3

Coronary artery ligation model for heart failure in the rat

Heart failure was induced using a sustained coronary artery ligation (CAL) model. Rats
were anesthetized by intraperitoneal injection with pentobarbital sodium (5 mg/kg body
weight), intubated, and artificially ventilated using a rodent respirator (model 683,
Harvard Apparatus). To induce myocardial infarction in the LV, the left main coronary
artery was ligated using a silk suture. For sham operation, the suture was placed in the
exact fashion, then was removed without any tying. All animals were housed singly per
cage after surgery. The animals sustained ligation for either 4 or 6 weeks without any
reperfusion of the coronary artery, then were euthanized for further analysis. The surgery
was performed by Dr. Karmazyn's staff, and the analyses performed for each trial are
listed in table 3.

2.1.4

Probiotic administration

Probiotic administration was provided immediately following the CAL or sham surgery.
Rats were provided 1 dose/day of probiotic in their drinking water for ad libitum
consumption for either 4 or 6 weeks. The water was changed daily. The specific surgeries
and probiotic treatments are listed in table 2. Based on typical daily water consumption, it
was estimated that the average probiotic dose in the active treatment group was 1.5 x 109
CFU/day.
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Table 2. Surgery and treatment assignments for animal studies

4 week pilot study

Group #

Surgery Treatment

1

CAL

Water

2

CAL

L. plantarum 299v

3

CAL

L. rhamnosus GR-1

1

Sham

Water

2

Sham

L. rhamnosus GR-1

3

CAL

Water

4

CAL

L. rhamnosus GR-1

5

CAL

Sterile skim milk

6

CAL

4 weeks L. rhamnosus

(n=5/group)

6 week study
(n=10/group)

GR-1 + 2 weeks sterile
skim milk
CAL: coronary artery ligation
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Table 3. Analyses performed for animal studies

Study

Parameters measured

4 week pilot study

Left ventricular hypertrophy, cardiac mechanical

(n=5/group)

function, bacterial cultivation of digesta

6 week study

Left ventricular hypertrophy, cardiac mechanical

(n=10/group)

function, left ventricular internal dimensions,
hemodynamics, blood cytokine and adipokine
concentrations, bacterial cultivation of digesta,
microbial profile analysis of cecum digesta

2.1.5

Echocardiography

Echocardiography evaluations were performed on each animal prior to CAL surgery and
probiotic treatment (week 0), and every 2 weeks thereafter until sacrifice. Rats were
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anesthetized with 2% isoflurane, placed in supine position on a heated platform. Images
were analyzed using the Vevo 770 Protocol-Based Measurements software
(VisualSonics, Canada) and calculations for the dimensions of the LV diameter were
taken using M-Mode 2 dimensional echocardiography images. Doppler measurements
were taken to determine peak early diastolic filling velocity (E wave), peak late diastolic
filling velocity (A wave), and E/A ratios. The echocardiography evaluations were
performed by Dr. Karmazyn's staff. The same reader conducted all evaluations blindly.

2.1.6

Hemodynamic measurement

Hemodynamic measurement was taken immediately prior to sacrifice, 6 weeks after CAL
or sham surgery. Rats were anesthetized with pentobarbital sodium (50 mg/kg body
weight), and an anterior thoracotomy was performed. The LV was catheterized once via
the right carotid artery using a 2.0F P-V Mikro-Tip catheter (Millar Instruments, USA),
and the left ventricular systolic and diastolic pressures were measured. The hemodynamic
measurement was performed by Dr. Karmazyn's staff.

2.1.7

Blood collection and chemokine/cytokine analysis

Immediately following hemodynamic measurements, 4 mL of blood was collected by
terminal bleeding directly from the heart and kept on ice in Vacutainer™ 10.8 mg K2
EDTA blood collection tubes (BD) until processing. Blood samples were centrifuged at
1000 x g for 10 minutes and plasma was stored at -80°C. The following nine cytokines
were chosen from The MILLIPLEX® MAP Rat Cytokine/Chemokine Magnetic Bead
Panel (EMD Millipore, Billerica, MA, USA) for blood cytokine analysis: Fractalkine,
GRO/KC, IFN-γ, IL-1α, IL-6, MCP-1α, MIP-1α, RANTES, and TNF-α. Blood plasma
samples were thawed to room temperature and the assay and analysis was performed
following the manufacturers protocol for the Bio-Plex 200® system (Bio-Rad,
Mississauga, ON).

2.1.8

Heart weight measurement and tissue processing

At sacrifice, the hearts were removed from the animals, images were obtained, and the
whole heart and dissected LV were weighed. Fifty to one hundred milligrams of tissue
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from the LV (non-ischemic region) of each heart from the six week-long study was
collected and stored at -80C for later ANP gene expression.

2.1.9

ANP gene expression analysis of left ventricular tissue

RNA was collected from the non-ischemic region of left ventricular tissue using QIAzol
Reagent (QIAGEN, Mississauga, ON) as per the manufacturer’s instructions. Reverse
transcription (RT) of RNA into cDNA for real-time quantitative polymerase chain
reaction (qPCR) analysis of ANP gene expression was performed using M-MLV Reverse
Transcriptase (Invitrogen, Burlington, ON) as per the manufacturer’s protocol. The realtime qPCR reactions were performed using SYBR Green Master Mix (Applied
Biosystems, USA), and gene products were quantified using a DNA Engine Opticon 2
thermal cycler. PCR conditions and primer sequences are summarized in table 4. The
housekeeping gene, 18S rRNA, was measured and quantified to normalize gene
expression levels using the standard curve method. The analysis was performed by Dr.
Karmazyn’s staff.
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Table 4. Gene primer sequences and cycle conditions used for real-time quantitative PCR
analysis of heart tissue
Gene

Forward Primer Sequence

Reverse Primers sequence

(5’-3’)

(5’-3’)

ANP

CTGCTAGACCACCTGGAGGA

AAGCTGTTGCAGCCTAGTCC

18S rRNA

GTAATCCCGTTGAACCCCATT

CCATCCAATCGGTAGTAGCG

Cycle

40 x (30 seconds @ 95°C , 25 seconds @ 60°C, 30 seconds @ 72°C)

conditions
ANP: atrial natriuretic peptide
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2.1.10

Cecum digesta sample collection and bacterial cultivation

After sacrifice, the cecum and colon were removed immediately. Three grams of cecum
and colon digesta were collected and frozen at -80°C until further use, or immediately
used for cultivation experiments. Fresh cecum and colon digesta (0.3 g each) were
resuspended in 1 mL sterile PBS. Serial dilutions (10-3-10-8) were made and 10 µL of
each was drop-plated in triplicate. The selective growth media listed in table 1 were used
to isolate colonies of both L. rhamnosus GR-1 and L. plantarum 299v. For isolating L.
rhamnosus GR-1, 32 µg/mL fusidic acid (FA) (Sigma, Mississauga, ON) was filter
sterilized and added to sterile MRS agar. For isolating L. plantarum 299v, Lactobacillus
plantarum Selective Media (LPSM) was used184. This medium has the same MRS
formulation except for the replacement of dextrose with sorbitol, and the addition of
0.02g/L bromocresol purple, and later 0.02 g/L filter sterilized ciprofloxacin to the sterile
agar medium. In the presence of bromocresol purple, the production of acid from sorbitol
by L. plantarum 299v turns the originally purple media yellow. MRS agar, MRS FA and
LPSM plates were incubated at 37C anaerobically for 48 hours and colonies were
enumerated.

2.1.11

Cecum microbiota analysis

Both the colon and cecum samples were cultivated on selective media immediately
following sacrifice. Once the colonies were isolated and enumerated it became apparent
that both sites had similar bacterial abundance. It has been reported that nearly all
endogenous metabolic activity by gut bacteria in the rat occurs in the cecum and colon
only185. Based on the levels of short chain fatty acids detected, the gut microbiota of the
cecum is more robust in fermenting and metabolism than the colon185. As metabolite
levels are indicative of the function and activity of the endogenous bacteria, this suggests
that the majority of gut microbial activity in the rat is housed in the cecum. Based on this,
and the similar results from the cultivation of cecum and colon digesta, it was decided to
consolidate the next-generation sequencing 16S rRNA gene analysis by investigating the
microbiota of cecum digesta only.
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Cecum digesta samples from the six week study were thawed to room temperature and
DNA was extracted using the QIAamp DNA stool mini stool kit (QIAGEN) according to
the manufacturer’s protocol with the following additional steps: approximately 0.2 grams
of digesta was suspended in the lysis buffer with a 90 second bead beating step prior to
95°C lysis. For optimal DNA yield, all centrifuge times were doubled and the final
incubation with the Buffer AE elution buffer was increased to 2 minutes. DNA from each
sample was immediately quantified using a Qubit® 2.0 fluorometer (Life Technologies,
Burlington, ON), and stored at -80°C.

2.1.12

Amplification of bacterial DNA

The V6 hypervariable region of the 16S rRNA gene was amplified from DNA template
extracted from each cecum digesta sample (refer to table 5 for primer sequences and
cycle conditions). Each left forward 5’ primer (V6LT) was tagged with a unique barcode
sequence at the 3’ end. This barcode enabled identification of the samples after the
sequencing. The right reverse primer (V6RT) contained an Ion Torrent adapter sequence
on the 5’ end.
Forty µL PCR reactions were prepared using 5 µL of DNA template per reaction, or 5 µL
of nuclease-free water as negative control. Each PCR reaction contained 1.5 mM MgCl2
0.8 µM each primer, 4 µL 10X PCR buffer (Invitrogen), 0.2 mM dNTPs, 0.05U GO Taq
polymerase (Invitrogen), and 0.1 µL 5% bovine serum albumin (Sigma). PCR was
performed as described using an Eppendorf Mastercycler® PCR machine (Eppendorf).
Amplification products were quantified using Qubit® fluorometer (Life Technologies) to
determine DNA concentration, and equimolar quantities were pooled and purified using
the QIAquick PCR purification kit (Invitrogen). V6 16S rRNA next-generation
sequencing using the Ion Torrent platform (Life Technologies) was then performed at the
London Regional Genomics Center, Robarts Research Institute, Western University, as
per the Center’s standard operating procedure.
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Table 5. Primer sequences and cycle conditions used for PCR amplification of DNA
extracted from cecum digesta samples.
16S rRNA gene

Primer sequence (5’-3’)

V6LT

CCATCTCATCCCTGCGTGTCTCCGACTCAG

V6RT

AC(A or G)ACACGAGCTGACGAC

PCR cycle

1 X (2 minutes @ 95°C)

conditions
25 X (1 minute @ 95°C, 1 minute @ 55°C, 1 minute @ 72°C)
V6LT: Left forward V6 primer
V6RT: Right reverse V6 primer
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2.1.13

Sequence Analysis

Raw sequence data was filtered, processed, and analyzed using a modified version of a
data analysis pipeline developed by Dr. Gregory Gloor (Department of Biochemistry,
Western University)186. Custom Perl scripts were used to assign barcoded reads to each
individual sample. For quality control, each bar-coded sequence required a minimum 500
reads. Reads were discarded that weren’t within 70 – 90 base-pairs in length between the
right and left primers. To avoid erroneous taxonomic assignment that is intrinsic to Ion
Torrent sequencing in cases of low abundance reads, sequences present at less than 0.5%
abundance were not kept for analysis. Sequences present at 0.5% abundance and greater
were clustered by similarity to a seed sequence at 97% identity using Uclust version
3.0.617187. The most abundant sequence in each cluster was designated as a
representative operational taxonomic unit (OTU). Taxonomic assignments were made
using Seqmatch from the Ribosomal Database Project188. Seqmatch data was parsed and
matched using the Greengenes database189. For multiple top matches with equal scores,
the highest common taxonomy was assigned to a given OTU. Classification was assigned
at either the family or genus level if the sequence alignment was less than a 95% match.
Taxonomic assignments were then arranged and presented using QIIME for 16S rRNA
analysis190 and microbial communities from each sample were compared using weighted
UniFrac beta-diversity analysis191.
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2.2
The effect of probiotic administration on
hypertrophic cardiomyocytes cultured in vitro
To assess the effect of probiotic administration on cultured cardiomyocytes, co-culture
assays were developed using neonatal rat ventricular cardiomyocytes (NVCM). Primary
NVCM cultures were isolated from 1-3 day old neonatal Sprague-Dawley rat pups by lab
staff of Dr. Karmazyn as previously described43 and in accordance with the guideline of
the Canadian Council on Animal Care (Ottawa, ON). For experiments, NVCM isolated
from the same litter were pooled to represent one biological replicate (one “n” value). I
developed assays to evaluate the effect of probiotic treatment on hypertrophic NVCM,
using cell surface area and gene expression measurements as indices of hypertrophy. The
specific procedures for each assay are described below.

2.2.1

Neonatal rat ventricular cardiomyocyte culture

NVCM were plated on Primaria™ (Falcon) culture dishes at optimal concentrations for
each co-culture experiment: 3 × 104 cells to allow room for growth and visualization for
cell surface area measurements and 6 × 104 cells to ensure sufficient RNA production for
gene expression experiments. Two mL of warm culture medium (table 6) was added to
each dish and the cells were maintained at 37°C 5% CO2. After 48 hours, cells were
washed with warm PBS-ABC (table 7) and the culture media was changed daily
thereafter. All reagents were tissue culture grade and filter sterilized or autoclaved. The
NVCM cell culture medium was adjusted to a pH of 7.10. Cells were maintained for
either 3 days for cell surface area experiments, or 5 days for gene expression
experiments, before commencing each experiment.
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Table 6. Culture medium reagents for NVCM cell culture
Chemical Name

Manufacturer/

Concentration

Catalogue #
DMEMF12 + HEPES

Gibco 11330-032

1L

NaHCO3

Sigma/S6014

30 mM

Fetal Calf Serum

Gibco 12483-020

10%

Transferrin

Sigma/T-0665

10 mg/L

Insulin

Sigma/I-5500

10 mg/L

Penicillin/Streptomycin

Gibco/15140-122

1%

Bromodeoxyuridine

Sigma/B-5002

0.1 mM

Linoleic Acid

Sigma/L-1012

5 mg/L

Bovine Serum Albumin

Gibco/15260-037

2 g/L

Sigma/A-4403

1%

Vitamin x 100

Gibco/11120-052

0.1%

Sodium Selenite

Sigma

10 µg/L

Pyruvic acid

Sigma

3mM

(Fraction V)
MEM Non-essential Amino
Acids

L-Ascorbic Acid

100 uM
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Table 7. PBS solutions for NVCM cell culture
Reagent

Chemical

Concentration

PBS A

NaCl

10 g/L

KCl

0.250 g/L

Na2HPO4·7H2O

2.71 g/L

KH2PO4

0.250 g/L

PBS B

CaCl2·2H2O

1.32 g/L

PBS C

MgCl2·6H2O

2.13 g/L

PBS ABCi

PBS A

80%

PBS B

10%

PBS C

10%

PBS: phosphate buffered saline
i

PBS ABC was prepared fresh from PBS A, PBS B, PBS C stocks at the beginning of

each NVCM cell culture experiment.
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2.2.2

Probiotic cultures and conditions

Five probiotic strains were used for NVCM co-culture experiments: Lactobacillus
rhamnosus GR-1, Lactobacillus rhamnosus CMPG10200, Lactobacillus reuteri RC-14,
Lactobacillus plantarum 299v, and Streptococcus salivarius K12.
Lactobacillus rhamnosus CMPG10200 is a mutant L. rhamnosus GR-1 strain (details are
provided in the next section). L. reuteri RC-14 is a vaginal clinical isolate, and S.
salivarius K12 is a probiotic strain used for oral health in the probiotic lozenge BLIS
K12® (BLIS Technologies, Dunedin, Otago, New Zealand). S. salivarius K12 was grown
in Todd Hewitt broth/agar.
The strains were resuscitated from -80°C freezer stocks kept at the Canadian Centre for
Human Microbiome and Probiotic Research (London, Ontario, Canada) and propagated
to second sub-cultures as described in the previous section. All strains were grown to 109
CFU/mL, anaerobically using the GasPak™ system (BD) at 37°C.

2.2.3

Msp1 knock out L. rhamnosus GR-1 strain CMPG10200

The major secreted protein (Msp1) produced by L. rhamnosus GR-1 is homologous to
p75192, the protein produced by L. rhamnosus GG that has shown to have anti-apoptotic
activity in intestinal cells136 and confers protection against I/R in the heart179. The Msp1
knock out mutant strain was kindly provided by Dr. Sarah Lebeer (Department of
Bioengineering, University of Antwerp, Belgium). The strain was constructed by
insertational mutagenesis192. Briefly, an internal fragment of the msp1 gene was
amplified by PCR and cloned into pCRII-TOPO vector. (Invitrogen). The vector was
digested with EcoRI and further ligated into an erythromycin-resistant vector. E. coli
TOP10F was transformed using this ligation product and the suicide vector was then
electroporated to L. rhamnosus GR-1. L. rhamnosus CMPG10200 was grown in MRS
broth/agar with the addition of 5 µg/mL erythromycin.
The Msp1 protein is a cell wall hydrolase that is necessary for daughter cell separation192.
This protein was of interest because in previous studies it was shown to protect against
ischemic injury in the heart and prevented stress-induced cellular apoptosis in intestinal
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epithelial cells136,178,179,193. Prior to receiving the strain, the absence of Msp1 knock-out
was confirmed by Western blot using anti-Msp1 antiserum. Microscopic examination of
the mutant also confirmed the absence of Msp1: While the mutant is able to grow to the
same density as the wild-type (WT), there is a clear defect of cell wall separation
visualized by bright-field microscopy (figure 1).
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Figure 1: Phase-contrast images of WT GR-1 and CMPG10200 strains
(a) WT GR-1 (40x); (b) CMPG10200 (40x); (c) WT GR-1 (100x). Arrows indicate WT
sites of cell septa; (d) CMPG10200 (100x)
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2.2.4

Probiotic treatment preparation

The probiotic treatments designed for the NVCM/probiotic co-culture experiments are
listed in table 8. Following resuscitation and propagation, 10 mL of the appropriate broth
media was inoculated from a single isolated colony of each probiotic strain from an agar
plate, and the culture was grown anaerobically at 37°C as described above. The broth
culture (109 CFU/mL) was used as the standard probiotic treatment for each strain. All
cultures were serially diluted and drop-plated onto the appropriate agar media to confirm
concentration.
To create the probiotic-conditioned media (PCM) with probiotic cells removed, 1 mL of
the broth culture was placed in a clean, sterile, microcentrifuge tube and centrifuged at
12,000 x g at 4°C for 5 minutes. The supernatant was carefully collected without
disturbing the bacterial pellet and transferred to a new, sterile microcentrifuge tube. This
centrifugation step was repeated, and the supernatant was transferred to a new sterile
microcentrifuge tube, to be used as the PCM treatment. Samples of the PCM treatments
were plated onto MRS agar to ensure no probiotic cells could be detected by cultivation.
Aliquots of the PCM were also either heat denatured (HD) by incubation at 80°C for 30
minutes or incubated in a 1:1 trypsin-EDTA (Gibco, Burlington, ON) solution at 37°C for
20 minutes. The trypsin-PCM (Tryp PCM) solution was then treated with a 0.05% trypsin
soybean inhibitor Glycine max (Sigma) to eliminate trypsin activity on the NVCM
culture. For filtered PCM treatments, the probiotic PCM was filtered using Centricon
Plus-20 centrifugal filters according to manufacturer’s instructions (Millipore). Both the
filtrate and retentate were collected and applied as a treatment.
The original bacterial pellet from the PCM treatment preparation was saved, washed with
ice cold sterile PBS, and centrifuged at 12,000 x g at 4°C. The supernatant was discarded
and the pellet was resuspended in 1 mL of sterile PBS. The pellet was then vortexed
thoroughly and the suspension was used as the live probiotic cell treatment, with PCM
removed. Aliquots of these cells were heat-killed (HK) by incubation at 80°C for 30
minutes. These cells were plated onto MRS agar to ensure no live probiotic cells were
present.
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All volumes of probiotic treatments used in the co-culture experiments were 50 µL,
unless otherwise stated. The average concentration of all probiotic cultures used in each
experiment was 109 CFU/mL.
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Table 8. Probiotic treatments for NVCM co-culture studies.
Probiotic Strain

Treatment

L. rhamnosus GR-1

Standard probiotic treatment (GR-1)
Live cells suspended in PBS (GR-1 cells)
Heat-killed cells suspended in PBS (HK GR-1 cells)
PCM (GR-1 PCM)
Heat-denatured PCM (HD PCM)
Centrifugal filtered PCM (PCM Filtrate/Retentate)
Trypsinized PCM (Tryp PCM)

L. rhamnosus CMPG10200 Standard probiotic treatment (CMPG10200)
Live cells suspended in PBS (CMPG10200 cells)
PCM (CMPG10200 PCM)
L. plantarum 299v

Standard probiotic treatment (299v)

L. reuteri RC-14

Standard probiotic treatment (RC-14)

S. salivarius K12

Standard probiotic treatment (K12)
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2.2.5

Induction of hypertrophy and probiotic administration

To induce hypertrophy in NVCM, the α1-adrenergic receptor agonist phenylephrine (PE)
was applied to the cells. Following 3 days of culture for cell surface area experiments and
5 days for gene expression experiments, 10 µM PE was added to each dish. After gently
swirling to distribute the PE, a probiotic treatment was immediately added to the NVCM
in triplicate. The dishes were gently swirled again, and incubated at 37°C, 5% CO2 for 24
hours. After the 24 hour co-culture, the medium was removed from each dish and
replaced with PBS. Media containing probiotic cells were spread-plated to determine
viability after the 24 hour co-culture.

2.2.6

Cell surface area measurement and analysis

The physical effect of probiotic administration on hypertrophic NVCM was evaluated by
taking cell surface area measurements. Cells were viewed and images were obtained
using phase contrast microscopy with the Nikon Eclipse TE2000 inverted microscope
(Nikon Instruments Inc., USA). Surface area measurements of 50 random cells from at
least 5 fields of view per dish (20x objective) were conducted blindly using the calibrated
NIS-Elements BR software (Nikon Instruments Inc., USA). The average cell surface area
per dish was used to calculate a total average cell surface area per treatment. The fold
change in surface area was determined by dividing the treatment average by the control
average. All experiments were repeated independently at least 5 times.

2.2.7

Gene expression of hypertrophic markers in NVCM cocultured with probiotics

In order to confirm that the change in cell surface area was due to an attenuation of
hypertrophy, the gene expression of the hypertrophic markers ANP and α-skeletal actin
(aSKA) were measured after a 24 hour treatment period. The analysis was performed
using the real-time qPCR technique, and all experiments were repeated independently 3
times.
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2.2.8

RNA extraction and purification

Following the 24 hour treatment period, the medium was aspirated off each dish and
stored in sterile a microcentrifuge tube at 4°C for later bacterial enumeration. 1 mL of
TRIzol (Invitrogen) was added to each dish. The cells were scraped thoroughly off of
each dish using a plastic cell scraper and the TRIzol mixture was transferred to an
RNase-free 1.5 mL microcentrifuge tube, vortexed, and incubated at room temperature
for 10 minutes. Two hundred µL of chloroform was added to each tube, vortexed
vigorously, and incubated at room temperature for 10 minutes. The tubes were then
centrifuged at 16,000 x g for 15 minutes at 4°C. 500 µL of the upper aqueous phase
containing RNA was carefully transferred into a new RNase-free microcentrifuge tube.
500 µL of 100% ethanol was added to each tube containing the aqueous RNA and the
tubes were vortexed for 20 seconds. 500 µL of the ethanol-RNA mixture was transferred
to a PureLink® RNA spin column (Life Technologies). The column was centrifuged at
12,000 x g for 15 seconds, and the flow through was discarded. This was repeated until
all of the ethanol-RNA mixture was passed through the column. Following the
PureLink® RNA mini kit protocol for binding, washing, and elution (Life Technologies),
RNA was recovered and quantified using the NanoDrop 1000 spectrophotometer
(Thermo Fisher Scientific, USA). Purity of RNA was quantified using 260/280 and
260/230 ratios. RNA quality cut-off was set at >1.75 and >1.8 for 260/280 and 260/230,
respectively. RNA quality was also confirmed by viewing products via electrophoresis in
a 1% agarose gel using 1x TAE stained with ethidium bromide, and viewed under UV
light using AlphaImager (Alpha Innotech Corporation, USA).
RNA samples falling under the quality limits underwent an ethanol precipitation protocol
as follows: 3 µL of sodium acetate and 90 µL of 100% ethanol were added to each RNA
sample for overnight precipitation at -20°C. The next day, RNA samples were
centrifuged at 16,000 x g for 20 minutes at 4°C. The supernatant was discarded and the
pellet containing crude RNA was resuspended in ice-cold 70% nuclease-free ethanol,
vortexed, and centrifuged at 16,000 x g for 20 minutes at 4°C. This step was repeated
once more. All the ethanol was removed from each tube using a fine pipette tip, and the
tubes were left open for 1 minute to evaporate the last of the ethanol. The crude RNA was
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then resuspended in 15 µL nuclease-free water, and quality was assessed using the
NanoDrop 1000 spectrophotometer, as described above. RNA samples were stored at 20°C until further processing.

2.2.9

Reverse transcription

Samples of RNA ranging from 300 ng – 2 µg were used as a template for RT PCR.
cDNA was synthesized using the High Capacity cDNA Reverse Transcription Kit
(Applied Biosystems, Canada). The master mix and cycle conditions for RT are listed in
table 9.
Ten µL of the RT master mix was combined and mixed with 10 uL of RNA sample (or
10 uL of nuclease-free water for the negative control) in an RNAase-free 96-well plate,
creating a 20 µL reaction. The PCR reaction was carried out in an Eppendorf
Mastercycler® PCR machine (Eppendorf). cDNA concentration was measured on all
negative controls and 3 random cDNA samples using a Qubit® 2.0 fluorometer (Life
Technologies) to confirm successful RT. The cDNA was then diluted into 340 µL of
nuclease-free water and stored at -20°C until further use.
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Table 9. Master Mix components for reverse transcription
Component

Volume/reaction (µL)

10x RT Buffer

2.0

25x dNTP Mix (100mM)

0.8

10x RT Random Primers

2.0

Multiscribe™ Reverse Transcriptase

1.0

Nuclease-free water

4.2

Final Volume

10
10 minutes @ 25°C

PCR conditions

120 minutes @ 37°C
5 minutes @ 85°C

RT: Reverse transcription
dNTP: deoxyribonucleotide triphosphate
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2.2.10

Quantitative real-time PCR

qPCR was used to evaluate the gene expression of the hypertrophic markers atrial
natriuretic peptide (ANP) and α-skeletal actin (aSKA), relative to a housekeeping gene,
in this case 18S rRNA. ANP, aSKA and 18S rRNA primer sequences were designed
using the Primer-BLAST tool from the National Center for Biotechnology Information
(NCBI)194. The sequences are listed in table 10.
The primers were stored in a stock solution containing 800 nM of both forward and
reverse primer. Prior to running the cDNA samples, the primers were validated using
serial dilutions of a positive control cDNA sample. Five µL of each serial dilution was
combined in triplicate with 10 µL Power SYBR Green Master Mix (Life Technologies),
and 5 µL of the 800 nM primer stock solution. The PCR reaction was then carried out in
a 384-well reaction plate using the 7900 HT Sequence Detection System (SDS) and
primer efficiencies were determined using SDS 2.3 Sequencing Software (Applied
Biosystems, Life Technologies). The efficiencies for 18S rRNA, ANP and aSKA
respectively were 97.24, 97.50 and 98.03%. The PCR products were then viewed via
electrophoresis in a 3% agarose gel using 1x TAE stained with ethidium bromide, and
viewed under UV light using AlphaImager (Alpha Innotech Corporation, Santa Clara,
CA, USA) (figure 2).
After primer validation, cDNA samples were used as template for qPCR reactions. 5 µL
of each cDNA sample was combined in triplicate with 10 µL Power SYBR Green Master
Mix (Life Technologies), and 5 µL of 800 nM primer stock solution. Each reaction was
carried out in triplicate for all 3 primers in a 384-well reaction plate using the same
machine and method as above.

2.2.11

Real-time quantitative PCR data analysis

Analysis was carried out using RQ Manager 1.2 Data Analyzer (Applied Biosystems,
Life Technologies). Relative gene expression of aSKA and ANP was determined using
18S rRNA as the endogenous control. Gene expression in a treatment cDNA sample
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measured in terms of relative quantification (RQ), using the comparative threshold cycle
(Ct) method. The Ct of the PCR reaction in which aSKA or ANP was detected was
compared to the Ct of detection for 18S rRNA. The total difference in Ct over 40 cycles
of PCR is then used to determine the RQ of a sample. RQ represents the fold change in
gene expression compared to a calibrator (untreated control cDNA sample). The RQ of
the calibrator = 1. The standard deviation (SD) of Ct values was used to determine the
quality of the technical replicates in each sample. If the SD was over 0.25, the RQ value
for that sample was considered unreliable and was not used in the data analysis.
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Table 10. Genes and primer sequences used for quantitative real-time PCR.
Gene

Primer Sequence
Forward: 5’-CAGAGTCAGAGCAGCAGAAACT-3’

aSKA (NM_019212.2)

Reverse: 5’-GTTGTCACACACAAGAGCGG-3’
Product size: 71 base pairs (BP)
Forward: 5’-CCCTCCGATAGATCTGCCCT-3’

ANP (NM_012612.2)

Reverse: 5’-TTCGGTACCGGAAGCTGTTG-3’
Product size: 148 BP
Forward: 5’-GTAACCCGTTGAACCCCATT-3’

18S rRNA

Reverse: 5’-CCATCCAATCGGTAGTAGCG-3’

(NR_046237.1)

Product size: 148 BP

PCR cycle conditions

40x (10 minutes @ 95°C, 15 seconds @ 60°C)
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Figure 2. PCR products from primer validation for real-time qPCR
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2.3

Statistical Analysis

All statistical analyses were performed using GraphPad Prism 5 and statistical analysis
reports for all NVCM experiments are provided in the appendix.
Data from CAL animal studies were reported as means ± standard error.
Echocardiographic data were analyzed using 2-way analysis of variance (ANOVA) with
repeated measures and a post hoc Tukey test and all other data were analyzed using a 1way ANOVA followed by a post hoc Tukey test. Differences were considered significant
when P < 0.05. Statistical analysis for the next-generation sequencing data was
performed using Uclust187, QIIME190, UniFrac191, and a modified version of a data
analysis pipeline published by Dr. Gregory Gloor186,195.
For NVCM experiments, technical triplicates for each experiment were performed on at
least 3 biological replicates. Data reported are means of biological replicates ± standard
deviation. Differences between means of the treatments were compared using a 1-way
ANOVA followed by a post hoc Tukey test, or by a Student’s t-test. Differences were
considered significant when P < 0.05.
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Chapter 3 : Results
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Results

3

3.1
Probiotic administration attenuates heart failure in
the rat
In both the 4 week pilot study and the 6 week study, probiotic administration attenuated
several parameters of HF after MI induced by CAL surgery. Overall, none of the
surgeries or treatments exerted any effect of body weight growth throughout the trials. In
terms of the outcome of HF, animals receiving L. rhamnosus GR-1 for 4 weeks, followed
by a 2 week treatment cessation period had the identical outcome as animals receiving L.
rhamnosus GR-1 for the entire 6 week trial. Herein, the data corresponding to “GR-1”
represents to the 6 week treatment group only. There was also no difference in outcome
in animals on the control skim milk treatment versus the control water treatment. Because
there was no sham group on skim milk treatment, it was decided to use the water control
group for the data analysis. Herein, the data corresponding to “water” represents the
control group for either sham or CAL operated animals. The outcomes on specific indices
for HF are described in detail in following sections.

3.1.1

Probiotic administration attenuates cardiac hypertrophy

Cardiac hypertrophy was measured by comparing the LV weight (LVW) to total body
weight (BW) for each animal. An increase in the LVW/BW ratio indicates left ventricular
hypertrophy. In both studies, CAL significantly increased LVW (P < 0.05). Figures 3 and
4 show that this was significantly attenuated by both L. rhamnosus GR-1 and L.
plantarum 299v administration (P < 0.05).
In the 6 week-long study, hypertrophy was also measured by ANP gene expression in the
LV. CAL significantly increased ANP expression, indicating a hypertrophic response in
the LV, 6 weeks post-surgery (P < 0.05). This response was nearly normalized with L.
rhamnosus GR-1 administration (figure 4).
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Figure 3. LVW/BW ratios in animals subjected to 4 weeks of CAL
The left ventricle of each animal was dissected and weighed at the end the study period.
The LVW/BW ratio was significantly reduced by GR-1 and 299v treatment. Error bars
indicate ± SEM (n=5). *P < 0.05 compared to CAL.
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Figure 4. LVW/BW ratios and LV ANP gene expression in animals subjected to CAL or
sham surgery for 6 weeks
The left ventricle of each animal was dissected, weighed, and processed for qPCR at the
end the study period. Gene expression of ANP was normalized to the 18S rRNA
housekeeping gene and is reported as a ratio to 18S rRNA expression. Error bars indicate
± SEM (n=10). * P < 0.05 compared to the sham group; #P < 0.05 compared to CAL +
water.
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3.1.2

Probiotic administration attenuates LV dysfunction post-CAL

Cardiac mechanical function was assessed by serial echocardiography. Animals were
analyzed immediately prior to surgery and probiotic treatment, and every two weeks
thereafter. Figures 5 and 6 show data from LV echocardiographic analyses performed
over the 4 week pilot study and the 6 week study respectively. CAL induced a significant
decrease in ejection fraction (EF) and fractional shortening (FS) and a significant increase
in early wave to atrial wave (E/A) ratio over the duration of both studies (P < 0.05). L.
rhamnosus GR-1 and L. plantarum 299v administration resulted in near-normalization of
these parameters. The left ventricular internal diameters (LVID) were also assessed in the
6 week-long study. Representative echocardiography images and the LVID systolic
(LVIDs) and LVID diastolic (LVIDd) are shown in figure 7. CAL significantly increased
LVID over 6 weeks (P < 0.05), although this was significantly attenuated with L.
rhamnosus GR-1 administration.
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Figure 5. Echocardiography data collected every 2 weeks for 4 weeks total of sustained
CAL
GR-1 and 299v treatment attenuated the CAL-induced decrease in EF and FS and CALinduced increase in E/A ratio. Error bars indicate ± SEM (n=5). * P < 0.05 from CAL +
GR-1 and CAL + 299v; #P < 0.05 compared to week zero.
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Figure 6. Echocardiography data collected every 2 weeks for 6 weeks total of sustained
CAL or sham surgery
GR-1 administration significantly attenuated the CAL-induced reduction in ejection
fraction and fractional shortening and increase in E/A ratio in animals over the 6 week
trial period. Error bars indicate ± SEM (n=10). * P < 0.05 compared to the CAL + GR-1,
sham + GR-1, and sham + water groups; +P < 0.05 from week zero (n=10).
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Figure 7. Representative images and corresponding quantified diastolic and systolic left
ventricular internal diameters from echocardiography evaluations
GR-1 treatment significantly attenuated the CAL-induced increase in LVID over the 6
week trial period. Error bars indicate ± SEM (n=10). *P < 0.05 compared to the CAL +
GR-1, sham + GR-1, and sham + water groups; +P < 0.05 from week zero.

66

3.1.3

Probiotic administration attenuates hemodynamic
dysfunction function post-CAL

At the end of the 6 week study, animals were subjected to catheter-based hemodynamic
analyses and the data is summarized in figure 8. The hemodynamic data indicates systolic
and diastolic dysfunction were induced by CAL. The left ventricular end systolic pressure
(LVSP) significantly decreased with CAL (P < 0.05), while the left ventricular end
diastolic pressure (LVEDP) significantly increased (P < 0.05). These abnormalities were
significantly improved with L. rhamnosus GR-1 treatment (P < 0.05). Similarly, there
was a significant reduction in cardiac output and stroke volume after 6 weeks of sustained
CAL that was attenuated with L. rhamnosus GR-1 treatment (P < 0.05).
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Figure 8. Hemodynamic parameters assessed by cardiac catheterization after 6 weeks of
sustained CAL
CAL induced abnormalities in left ventricular end systolic and diastolic pressure (LVSP,
LVEDP), cardiac output, and stroke volume after the 6 week trial period. These
abnormalities were significantly improved with GR-1 treatment. Error bars indicate ±
SEM (n=10). *P < 0.05 compared to respective sham group. #P < 0.05 compared to CAL
+ water group.
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3.2
Probiotic administration has no effect on serum
cytokine levels
To determine whether or not probiotic administration alters the levels of inflammatory
factors involved in the cardiac remodeling process, serum samples were assayed for
levels of 9 cytokines after the 6 week CAL period. Any individual sample within a group
where a cytokine was not detected was excluded from the analysis. TNF-α values for all
samples fell below the threshold detection limit and therefore the data are not reported.
For all the other detectable values, there were no significant changes in concentration
across all the groups (figure 9).
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Figure 9. Concentration of 8 pro-inflammatory cytokines detected in plasma of animals
taken 6 weeks post-CAL or sham surgery
There was no significant difference in concentration of any of the cytokines across all
treatment groups (n=6-10)
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3.3
Probiotic administration improves CAL-induced
increase in plasma leptin to adiponectin concentration
ratio
Two adipokines, leptin and adiponectin, were assayed for serum concentration following
6 weeks of CAL. These adipokines are considered to have antagonistic function against
each other, and are associated with chronic HF47,52,196. CAL significantly increased serum
leptin levels (P < 0.05) but not serum adiponectin. There was a two-fold increase in
leptin, when normalized to adiponectin. These CAL-induced changes were significantly
attenuated with L. rhamnosus GR-1 administration (P < 0.05). These data are
summarized in figure 10.
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Figure 10. Plasma leptin and adiponectin levels 6 weeks post-CAL and sham surgery
GR-1 treatment significantly attenuated the CAL-induced increase in plasma leptin levels
and plasma leptin/adiponectin ratio. Error bars indicate ± SEM (n=8). *P < 0.05
compared to sham + water; #P < 0.05 compared to CAL + water.
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3.4
Probiotic lactobacilli were found viable in the
cecum and colon digesta
L. rhamnosus GR-1 and L. plantarum 299v were readily cultivated from fresh cecum and
colon digesta samples on selective MRS agar (table 11 and table 12). The successful
cultivation of L. plantarum 299v was indicated by the purple LPSM agar turning bright
yellow due to sorbitol fermentation by L. plantarum 299v. Neither L. rhamnosus GR-1
nor L. plantarum 299v were successfully cultivated on selective media from digesta
samples of rats in milk or water controls. Representative images of isolated colonies are
displayed in figure 11.
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Table 11. Cultivation of probiotic colonies on selective agar media from cecum and
colon digesta samples collected 4 weeks post-CAL. The data represents the average
CFU/mL in each group (n=10)
Cecum (CFU/mL)

Colon (CFU/mL)

Group

MRS FA

LSPM

MRS FA

LPSM

CAL

Not detected

Not detected

Not detected

Not detected

GR-1

6.59 x 108

Not detected

1.52 x 109

Not detected

299v

Not detected

5.77 x 105

Not detected

5.49 x 105
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Table 12. Cultivation of probiotic colonies on selective agar media from cecum and
colon digesta samples collected 6 weeks post-CAL or sham surgery. The data represents
the average CFU/mL in each group (n=10)
Group

Cecum (CFU/mL)

Colon (CFU/mL)

1 (Sham + water)

Not detected

Not detected

2 (Sham + GR-1)

8.71 x 107

8.81 x 107

3 (CAL + water)

Not detected

Not detected

4 (CAL + GR-1)

6.73 x 107

5.67 x 107

Not detected

Not detected

7.56 x 104

6.58 x 104

5 (CAL + skim milk)
6 (CAL + GR-1 4wks/milk
2wks)
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Figure 11. Representative images of agar plates inoculated with cecum digesta from
animals from the 4 week pilot study
Top: Purple LPSM plate inoculated with cecum digesta from the CAL only group
showing no cultivation of bacteria Middle: The originally purple LPSM plate turned
yellow after inoculation by cecum digesta from the 299v group and produced isolated
colonies. Bottom: Isolated colonies on MRS FA plate inoculated with cecum digesta
from the GR-1 group.
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3.5
Probiotic administration does not affect the
microbial composition of cecum digesta
Sequencing of the V6 region of the 16S rRNA gene generated 2,254,397 total usable
reads from 60 cecum digesta samples collected from the animals in the 6 week study.
Three samples did not run successfully and were excluded from the analysis (1 each from
group 2, 3, and 5). Using a minimum of 0.5% abundance threshold for any sample and a
≥97% sequence identity, there were a total 242 distinct organizational taxonomic units
(OTU) groupings (figure 12). GR-1 was not detected in any of the 60 individual samples.
A heat map displaying the 50 most abundant OTUs detected in the cecum digesta
samples was generated and is displayed in figure 13. Community level variance was
evaluated using the ANOSIM nonparametric statistical method in QIIME. There was no
significant variance in microbial composition across the 6 treatment groups (R=0.1308).
Although OTU 0 appears to have variable abundance, one-way ANOVA testing indicates
that the variation is not significant (P > 0.05). Overall, there was no distinct grouping of
community compositions in any of the 60 samples, with respect to probiotic
administration. Weighted β-diversity UniFrac analysis-generated Principal Coordinate
Analysis (PCoA) plots were generated to display the dissimilarities in community
compositions of each sample (figure 14). There was no distinct grouping cecum digesta
samples from rats that received CAL surgery compared to sham, or rats that received L.
rhamnosus GR-1 compared the placebo treatment. This indicates that the both the CAL
surgery and probiotic treatment did not induce significant changes to the microbial
composition of the gut after 6 weeks of treatment.
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Figure 12. Bar plot displaying the microbial composition of cecum digesta
Each vertical bar represents the microbial profile of one individual animal (n=57). Each
colour represents a specific OTU detected in the digesta sample by 16S rRNA nextgeneration sequencing (see colour legend). The amount of each colour in the vertical bar
represents the relative abundance of the OTU.
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Legend to accompany figure 10 bar plot. Each OTU was assigned taxonomy based on
BLAST (NCBI) and Greengenes gene sequence alignment. Alignments with less that
97% identity were classified no higher than the genus level.
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Legend (continued) to accompany figure 10 bar plot. Each OTU was assigned taxonomy
based on BLAST (NCBI) and Greengenes gene sequence alignment. Alignments with
less that 97% identity were classified no higher than the genus level.
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Figure 13. Heat map displaying the 50 most abundant OTUs detected in cecum digesta
samples using 16S rRNA next-generation sequencing
Each vertical bar represents the cecum digesta microbiota of one individual animal
(n=57).
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Figure 14. Weighted β-diversity UniFrac analysis-generated PCoA plots
The plots display dissimilarities in microbial community compositions of each sample.
Samples with highly dissimilar microbial compositions are spaced far apart from each
other. A: PCoA plot of communities from animals receiving sham surgery with skim
milk treatment compared to animals receiving CAL surgery with skim milk treatment. B:
The comparison of communities from animals on GR-1 treatment versus control
treatment (skim milk or water).
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3.6
Probiotics co-cultured with neonatal rat ventricular
cardiomyocytes (NVCM) attenuate phenylephrineinduced hypertrophy
It was hypothesized that probiotics will provide a direct beneficial effect to
cardiomyocytes under conditions that simulate HF. To test this, probiotic treatments were
applied to NVCM culture following the administration of PE – a hypertrophic agent. To
assess the outcome of the probiotic NVCM co-culture, the cell surface area of the cell and
gene expression of hypertrophic markers was measured after 24 hours of treatment.
Except for the average cell surface area data across all biological replicates, expressed in
µm2, the treatment-induced changes are reported as the fold change compared to the
control. NVCM isolated from different litters may inherently grow at slightly different
rates and sizes and therefore the fold change in surface area and gene expression was
calculated to account for those differences. Fold change calculations are the ratio of
treated to untreated measurements and the values represent one biological replicate.

3.6.1

PE administration induces hypertrophy in NVCM

In order to determine the hypertrophic response to PE administration, and to rule out that
MRS broth affects the growth of cultured NVCM, 50 µL of sterile MRS broth was added
NVCM culture with or without PE. Twenty four hour PE exposure induced an average
1.41-fold increase in NVCM surface area, compared to untreated control cells. PE with
MRS broth induced a 1.35 fold increase in cell surface area. The difference in cell surface
area compared to both of these treatments was statistically significant (P < 0.05), but
difference between the two PE treatments without MRS broth was not significant (P =
0.52). Without PE, The average fold change in surface area of cells cultured with MRS
broth compared untreated cells after 24 hours was 1.02. A student’s t-test, was performed
to determine the difference between MRS broth-treated and untreated cells. The
difference was not significant (P = 0.75).
The gene expression of the hypertrophic markers ANP and aSKA was evaluated to
confirm a hypertrophic response in NVCM exposed to PE. The administration of PE
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induced a 1.91-fold and 1.51-fold increase in gene expression of ANP and aSKA,
respectively. The administration of PE with 50 µL of sterile MRS broth induced a 2.01fold increase in gene expression of ANP, and a 2.10-fold of aSKA. The difference in
ANP expression with both PE and PE + MRS broth compared to untreated cells was
statistically significant (P < 0.05), but the difference between the two PE treatments was
not statistically significant. There was no statistically significant difference in expression
of aSKA between PE and untreated cells (P = 0.0921), likely because of the high
standard deviation in the PE group. There was, however, a significant difference in aSKA
expression between MRS broth and PE + MRS broth (P < 0.01).
The administration of MRS broth without PE produced a 0.96 and 0.79-fold change in
gene expression of ANP and aSKA, respectively, over 24 hours, compared to untreated
cells. A student’s t-test was performed to determine the difference in gene expression
between untreated and MRS broth-treated NVCM. The expression of ANP and aSKA
were both found to be not significantly different (P = 0.1160 and P = 0.1909,
respectively).
These results confirm that PE administration induced hypertrophy over 24 hours in
NVCM. The presence of sterile MRS broth has no effect on the growth of NVCM.

84

Figure 15. PE induces hypertrophy in NVCM
A: The NVCM surface area following 24 hour MRS broth culture with or without the
administration of PE (n=5). B: The fold change in NVCM surface area compared to
untreated (control) cells, following 24 hour MRS broth culture with or without the
administration of PE (n=5). C, D: The fold change in gene expression of ANP and aSKA,
respectively in NVCM (n=3). *P < 0.05 and **P < 0.01 compared to control and MRS
broth. Error bars indicate the standard deviation.
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3.6.2

L. rhamnosus GR-1, L. plantarum 299v, and S. salivarius
K12 co-cultured with NVCM did not affect viability of NVCM

NVCM co-cultured with L. rhamnosus GR-1, L. plantarum 299v, and S. salivarius K12
had normal cell morphology after 24 hours, as indicated by the representative
micrographs in figure 16. In addition, the cells were spontaneously beating, an indication
(however not a prerequisite) of NVCM viability. The probiotics were also successfully
isolated from the culture media 24 hours after co-culture with NVCM, indicating that
they were not susceptible to the penicillin/streptomycin antibiotic solution in the NVCM
culture medium.
The majority of NVCM co-cultured with L. reuteri RC-14 did not survive the 24 hour
treatment period, as evidenced by loss of cell attachment and abnormal morphology
(figure 16). A scarce number of NVCM cultured with L. reuteri RC-14 were beating after
the 24 hour treatment period. The L. reuteri RC-14 cells also did not survive the
treatment period, as they were unsuccessfully isolated from the culture medium.
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Figure 16. Representative micrographs illustrating NVCM exposed to PE alone or with
probiotics
The control NVCM were either untreated, or co-cultured with MRS broth. Original
magnification = 20×
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3.6.3

L. rhamnosus GR-1 administration inhibits PE-induced
hypertrophy in NVCM

When L. rhamnosus GR-1 was co-cultured with NVCM immediately following PE
administration, there was no increase in NVCM surface area compared to untreated cells.
The inhibition of hypertrophy was confirmed by the gene expression of ANP and aSKA
relative to untreated cells. The expression of both hypertrophic markers was significantly
reduced when NVCM cells exposed to PE were co-cultured with L. rhamnosus GR-1 (P
< 0.05).
To confirm the presumption the live probiotic cells are required to confer an antihypertrophic effect, L. rhamnosus GR-1 cells were HK by incubation at 80°C for 30
minutes. HK GR-1 cells and live GR-1 cells had the same average cell surface area,
however, when the data was normalized by calculating the fold change in cell surface
area, there was a loss of anti-hypertrophic activity in HK GR-1 cells. The difference in
gene expression of ANP in PE-treated NVCM without HK GR-1 cells and PE-treated
NVCM with HK GR-1 cells was not statistically significant. For both ANP and aSKA,
there was a slight increase in gene expression with HK GR-1 cells, compared to live L.
rhamnosus GR-1. The increase, however, was not statistically significant. (P = 0.35 and
0.36 for ANP and aSKA respectively). These data are summarized in figure 17.

88

Figure 17. L. rhamnosus GR-1 inhibits PE-induced hypertrophy in NVCM
A: The NVCM surface area following 24 hour co-culture with GR-1 (n=5). B: The fold
change in NVCM surface area compared to untreated (control) cells, following 24 hour
co-culture with GR-1 (n=5). C, D: The fold change in gene expression of ANP and aSKA
in NVCM (n=3). Unless otherwise stated, all volumes of GR-1 treatments were 50 µL (1
x 109 CFU/mL stock culture). *P < 0.05 and **P < 0.01 compared to all other treatments.
#

P < 0.05 compared to PE + MRS broth. Error bars indicate the standard deviation.
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3.6.4

Inhibition of the PE-induced hypertrophy in NVCM is not
probiotic strain specific

The attenuation of PE-induced hypertrophy by probiotics was not limited to the L.
rhamnosus GR-1 strain. Based on the cell surface area and gene expression of ANP and
aSKA after 24-hour co-culture, L. plantarum 299v and S. salivarius K12 inhibited the
PE-induced hypertrophy in NVCM. There was a significant decrease in ANP and aSKA
gene expression in NVCM co-cultured with L. plantarum 299v compared to the control
(P < 0.05). These data are summarized in figure 18.
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Figure 18. L. plantarum 299v and S salivarius K12 inhibits PE-induced hypertrophy in
NVCM
A: The NVCM surface area following 24 hour co-culture with 299v and K12 (n=5). B:
The fold change in NVCM surface area compared to untreated cells, following 24 hour
co-culture with 299v and K12 (n=5). C, D: The fold change in gene expression of ANP
and aSKA compared to untreated NVCM after 24 hour co-culture with 299v and K12
(n=3). All volumes of 299v and K12 treatments were 50 µL (1 x 109 CFU/mL stock
culture). *P < 0.05 and **P < 0.01 compared to all other treatments. +P < 0.05 compared
to MRS broth. Error bars indicate the standard deviation.
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3.6.5

Msp1 is not required for inhibiting PE-induced increase in
NVCM surface area

Msp1 produced by Lactobacillus rhamnosus was of interest because it has shown to
protect against ischemic injury and stress induced apoptosis in the heart and small
intestine. We obtained a mutant msp1 knock out L. rhamnosus GR-1 strain to test
whether or not this protein is beneficial to NVCM. When CMPG10200 was co-cultured
with NVCM immediately following PE administration, there was a similar inhibition of
PE-induced increase in NVCM surface area as seen with the WT L. rhamnosus GR-1
strain (figure 19). This suggests that the protein Msp1 is not required for preventing cell
surface area increase in NVCM exposed to PE, and therefore, gene expression analysis
using this strain was not pursued.

92

Figure 19. L. rhamnosus GR-1 Msp1 knock out strain CMPG10200 inhibits PE-induced
hypertrophy in NVCM
Top: The NVCM surface area following 24 hour co-culture with CMPG10200 (n=5).
Bottom: The fold change in NVCM surface area compared to untreated cells, following
24 hour co-culture CMPG10200 (n=5). All volumes of CMPG10200 treatments were 50
µL (1 x 109 CFU/mL stock culture). **P < 0.01 compared to all other treatments. Error
bars indicate the standard deviation.
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3.6.6

PE-induced hypertrophy in NVCM is attenuated by PCM
treatment alone

When NVCM were treated with GR-1 PCM void of any live bacteria, the PE-induced
increase in cell surface area and gene expression of ANP and aSKA was significantly
attenuated, similar to treatments with live probiotic cells (P < 0.05). I hypothesized that
PCM contains a soluble protein that could directly prevent PE-induced increase in cell
surface area. Various assays were performed to test this hypothesis, and the results are
summarized in figure 20. First, Attempts were made to elucidate the size of the potential
anti-hypertrophic factor by centrifugally filtering the PCM. While the overall surface area
of cells indicates that both the filtrate and retentate retained an anti-hypertrophic effect,
the fold-change in cell surface area indicates that this effect was lost.
Second, the proteins were destabilized by heat denaturing the PCM by a 30 minute
incubation at 80°C and by trypsin treatment. Heat denaturation resulted in a loss of antihypertrophic activity of the PCM, as indicated by the fold change in NVCM surface area
and ANP gene expression. In NVCM co-cultured trypsin-treated PCM, the attenuation of
PE-induced increase in ANP gene expression was lost. There was an increase in PEinduced aSKA gene expression with HD and trypsin-treated PCM compared to regular
PCM, however the difference was not significant. Heat denatured PCM significantly
attenuated the PE-induced increase in aSKA expression (P < 0.05).
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Figure 20. PCM inhibits the PE-induced hypertrophy in NVCM
A. NVCM surface area following 24 hour co-culture with various PCM treatments (n=5).
B: The fold change in NVCM surface area compared to untreated cells, following 24
hour co-culture with various PCM treatments (n=5). C, D: The fold change in gene
expression of ANP and aSKA compared to untreated NVCM after 24 hour co-culture
with various PCM treatments (n=3). Unless otherwise stated, all PCM volumes were 50
µL. *P < 0.05 and **P < 0.01 compared to all other treatments. #P < 0.05 compared to PE
+ MRS broth. ×P < 0.05 compared to PE + Tryp GR-1 PCM. Error bars indicate the
standard deviation.
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4

Discussion

This thesis describes novel applications of probiotic lactobacilli to cardiovascular health.
Using an animal model and in vitro experimentation, Lactobacillus rhamnosus GR-1, a
probiotic known to transit the intestinal tract and confer benefits there and in the
urogenital tract, was found to induce improved modeling of heart tissue following
ligation injury simulate a heart attack. These results are the first to report that probiotic
administration can attenuate cardiac hypertrophy and HF in a rat model, and can protect
against hypertrophy in cardiomyocyte culture. This work adds to those studies already
described in the existing literature showing that probiotic administration can confer
cardiovascular health benefits via: (i) reduction of hypertension through production of
ACE-inhibitory peptides in the gut175-177, (ii) reduction of serum cholesterol by strains
expressing BSH174,197 or by active reduction and excretion of cholesterol 169,170 and (iii)
their protection against cardiac ischemia/reperfusion injury179,180.
With the incidence of CVD worldwide reaching alarming rates, there is a need for novel
prevention and treatment strategies. The five-year 50% mortality rate for HF patients
indicates that early detection and treatment is critical to improving outcomes. Previous to
the research for this thesis, the use of probiotics as a treatment for HF has never been
investigated. The present research suggests a unique application for probiotics and sheds
light on a potential novel mechanism of action of probiotics.

4.1
The salutary effects of probiotic administration in
the CAL-induced rat model of heart failure
In a preliminary 4 week-long pilot study, the benefit of two probiotic strains on the
outcome of heart failure in rats was evaluated using the CAL model for MI-induced HF
in rats. The CAL model differs from the I/R surgery used previously to examine L.
plantarum 299v, in that there is no release of the infarction-inducing ligature throughout
the duration of the study. Considering that both L. plantarum 299v and L. rhamnosus
GR-1 demonstrated identical benefit to rats in terms of echocardiography imaging, the
salutary effect of this probiotic therapy is likely not strain or species specific. This is an
interesting point, considering the extremely different ecological environments from
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which each of these strains was isolated. L. plantarum 299v is a strain isolated from the
human gastrointestinal tract and is marketed as a treatment to relieve symptoms of
irritable bowel syndrome128. L. rhamnosus GR-1 is a distal urethral strain that has the
ability to reduce urogenital pathogens and is used to treat bacterial vaginosis134,183,198 and
prevent UTI134,199-201 as well as enhance immunity in HIV patients202,203. The ability of
these two strains to improve outcomes of HF speaks to the universality of some of the
health benefits conferred by probiotics and their ability to affect organs throughout the
entire body204,205.
To follow-up on the pilot study, a 6 week-long study was performed including shamoperated and placebo control groups using L. rhamnosus GR-1 alone. To determine the
effect of treatment cessation, one group of animals received L. rhamnosus GR-1 for the
initial 4 weeks post-CAL surgery and then were placed on a placebo treatment for the
remaining 2 weeks. Identical beneficial effects of L. rhamnosus GR-1 were evident in
this group as for the group on L. rhamnosus GR-1 treatment for the entire 6 week period.
This suggests that the probiotic induced an effect early after surgery. Since this study did
not include L. rhamnosus GR-1 treatment for only the final few weeks of the trial, it is
difficult to estimate an exact timeframe. Although MI-induced damage to the
myocardium cannot be entirely prevented, the subsequent compensatory response of
cardiac remodeling and maladaptive hypertrophy begins as early as 2-3 days after
injury30. Preventing the progression of this response is key for preventing the progression
of HF16,30. Probiotic L. plantarum (WCFS1 as distinct from 299v) can induce differential
expression of gene reporters within an hour after ingestion206, thus it is reasonable to
imagine an effect within days for GR-1.
The ability to improve cardiac remodeling and ventricular dysfunction in patients with
HF, likewise, is a treatment of great interest. Using the same model for CAL-induced HF
in the rat as this study, it has been demonstrated that ginseng, administered in drinking
water to rats 4 weeks post-surgery, can reverse established CAL-induced hypertrophy207.
Unlike the probiotic mechanism examined herein, ginseng has been reported to act by
upregulating the expression of MMP-2 and MMP-9208. This is particularly interesting as
it indicates more than one way to improve heart function. Although, to verify that these
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effects are not somehow rat specific, it would be important to test the concept in another
animal and in humans.

4.1.1

The effect of probiotic therapy on cardiac function,
hemodynamics and cardiac hypertrophy in the CAL model
for heart failure

Echocardiography and cardiac catheterization, widely used in the clinic to track HF, were
used to monitor the effect of CAL surgery. With the added benefit of ex vivo analysis of
blood and heart tissue following euthanasia of the animals at the end point of the studies,
this provided novel insight into the effect of probiotic therapy on the outcome of HF and
the potential clinical applications.
Echocardiography is an essential diagnostic tool for diagnosing and tracking HF. This
non-invasive method is used to image physical abnormalities of the heart as well as
overall cardiac mechanical function. Indices such as FS, EF, and E/A ratio, all of which
were analyzed here, are especially important in detecting LV dysfunction. EF values
indicate the amount of blood that is pumped out of the ventricle with each contraction.
Healthy values range between 55 and 60%, whereas HF patients can have EF under
40%209. A low EF can result in inadequate blood circulation for the physiological needs
of the body. Half of HF patients have reduced EF, while the others are patients with
preserved EF, also known as diastolic LV dysfunction210. The latter experience normal
systolic contraction, but abnormal ventricular filling during diastolic contraction
(ventricular relaxation).While the outcome of HF with preserved EF is similar to that in
patients with reduced EF, patients with the former risk misdiagnosis and lack of proper
treatment due to the inability to detect diastolic LV dysfunction210. Accordingly, other
parameters, such as FS and the E/A ratio are important for tracking HF.
Both FS and E/A ratio are a measure of LV function. FS is a ratio of diastolic dimension
of the ventricle compared to systolic. Decreased FS suggests either diastolic dysfunction
(the LV does not properly relax), or systolic dysfunction (the LV does not contract
enough). The E/A ratio is obtained by tracking the velocity of blood flow across the
mitral valve into the LV. The early (E) wave represents passive filling during ventricular
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diastole, while the atrial or after (A) wave represents active filling with atrial systole. In
healthy patients, the E wave is slightly greater than the A wave, however in HF, the A
wave is greater than the E wave, indicating diastolic dysfunction211. The E/A ratio,
therefore, is useful for detecting diastolic dysfunction where EF may still be preserved.
Serial echocardiography performed throughout these studies indicated that L. rhamnosus
GR-1 and L. plantarum 299v administration not only attenuated the deterioration in
cardiac mechanical function caused by CAL surgery, but essentially normalized the
parameters that were assessed. Remarkably, animals on probiotics experienced no
significant changes in EF, FS, or E/A ratio compared to sham operated animals over the
duration of the studies. As demonstrated in the echocardiography data, the consequences
of CAL-induced myocardial infarction in terms of these parameter manifested within two
weeks post-surgery. This supports the notion that the salutary effects of probiotic
administration on these animals occur early after CAL surgery and are maintained even
as therapy is withdrawn.
Abnormalities in the hemodynamic properties of the heart are a strong risk factor and
diagnostic marker for HF. Following myocardial infarction, the damage sustained to the
myocardium sets off compensatory changes that result in an increase in blood volume
and pressure within the LV. At the same time, infarction also compromises the
contractility of the LV, which results in a decreased output and increased overload of
blood in the LV with each rhythmic cycle. These pathologies perpetuate the
hemodynamic abnormalities of the LV, and become a major complication in HF patients.
To monitor hemodynamic properties, catheterization is often required. Results from this
minimally invasive technique are usually compared to echocardiograms and are used as a
diagnostic tool for vascular and hemodynamic abnormalities. LVEDP is a reflection of
intravascular volume and pressure that affects ventricular performance, and is an
important parameter for tracking HF212. Elevated LVEDP is common following MI and
may result in clinical manifestation of HF, however, due to several other confounding
factors, it is a poor independent predictor of HF212.
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The catheter-based hemodynamic assessment on animals after 6 weeks of sustained CAL
indicate that the surgery induced several hemodynamic abnormalities in the LV. Similar
to EF, the cardiac output and stroke volume was significantly reduced in animals with
CAL, indicating an insufficient volume of blood cycling out of the heart. The LVEDP
was also increased, confirming a manifestation of HF induced by CAL surgery. All of
these pathologies were significantly attenuated with L. rhamnosus GR-1 administration,
but not normalized. This is likely because the infarction of the LV causes irreversible
damage to the heart that results in an unpreventable increase in LVEDP, regardless of any
treatment administered post-infarction.
Rather than evaluate the direct damage sustained to the LV by CAL surgery, this CAL
model was designed to assess the compensatory response that initiates and progresses
with HF. Because there was no release of the ligation or reperfusion of the coronary
artery, the CAL surgery induced cardiac hypertrophy that is a hallmark feature of HF and
occurs secondary to myocardial infarction. This hypertrophic response is one of the key
therapeutic targets for HF patients, as the initially adaptive hypertrophy eventually
becomes maladaptive, and often coincides with impaired EF, cardiac output, and
increased LVEDP. The compromised cardiac mechanical function in HF may be
considered a direct consequence and symptom of the maladaptive compensatory response
that occurs after MI. The evidence of improved cardiac mechanical function and LVEDP
in CAL animals receiving L. rhamnosus GR-1 treatment suggests that the underlying
mechanism lies in an attenuation of the maladaptive compensatory response to MI.
Indeed, upon assessing cardiac hypertrophy, L. rhamnosus GR-1 significantly attenuated
the CAL-induced increase in LVW and ANP gene expression. In the four week study, a
reduction in cardiac hypertrophy by L. plantarum 299v was also determined by
LVW/BW assessment. This impressive outcome suggests a novel application for
probiotics. Related studies have explored the use of probiotics as a protective treatment
prior to a major cardiac event such as MI, while these results indicate that probiotics are
also effective in improving the recovery following such an event.
Clinically, these findings have major implications. The immediate intervention strategies
for reducing the severity of ischemia during MI have improved mortality in recent years,
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yet the risk of developing HF still remains high17. The recovery process that precedes and
persists throughout the stages of HF is a critical therapeutic target post-MI. The
parameters analyzed in these studies are among some of the key factors for diagnosing
HF, as well as therapeutic targets. The current treatment strategies rely on β-blockers and
ACE-inhibitors to reduce contractility, slow the heart rate, and reduce blood pressure210.
While these drugs can improve the symptoms of HF, there still remains a therapy to be
developed that will effectively prevent HF. Newly diagnosed HF patients unfortunately
face the reality of long-term medication in order to manage the disease. HF is most
common in adults over 65 years old213 and often these patients are already taking
medication for other chronic conditions. The impact of chronic medication plays a
significant role in patients’ lives. First, the cost of HF medication in addition to other
medications, is substantial. A study assessing the cost of HF medication to outpatients in
the US found that medication for HF alone cost $340 per month213. For patients with HF
and other non-cardiovascular comorbidities such as chronic obstructive pulmonary
disease and diabetes, medication costs $600 per month213. The cost of medication for
patients with severe heart failure was significantly higher than those with mild heart
failure, indicating that as the disease progresses, more medication is required213. For
patients without access to health insurance and lacking personal financial resources, these
costs stand as a strong deterrent for medication compliance. Prescribed dosing may be
altered or stopped altogether to decrease cost. Lack of sufficient medication can
exacerbate the progression of HF and eventually result in hospitalization and further
economic burden. Based on the suggested retail price of a product containing one of the
probiotic strains tested here and assuming the dosing would remain the same then the cost
would be less than $40 per month. While it is unlikely that probiotics will entirely replace
current treatment regimens for heart failure, combination therapy could improve the
financing.
Probiotics also provide additional benefits that cannot be offered by standard HF
medications. In addition to high cost, the chronic use of HF medications such as βblockers and ACE-inhibitors, or any pharmacological agent, brings risk of adverse side
effects. The most common side effects of both β-blockers and ACE-inhibitors are cough,
dizziness, hypotension, and bradycardia214,215. Impaired renal function is a risk with
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ACE-inhibitor medication that increases proportionally to dose. This side effects are
often managed by additional medication which altogether complicates the issue of costs
and risks associated with chronic medication. Again, non-compliance may become a
serious issue for patients unable to cope with the requirements of chronic medication. The
use of a probiotic, with very low occurrence of adverse effects and several systemic
nutritional and health benefits, in addition to or as a replacement for pharmaceutical
drugs, is worthy of consideration for preventing progression of HF while minimizing
adverse effects of chronic medication. The ability of L. rhamnosus GR-1 and L.
plantarum 299v to prevent the CAL-induced HF is an exciting finding. Neither strain has
been evaluated for ACE-inhibitory activity, however other L. rhamnosus and L.
plantarum strains have both been reported to produce ACE-inhibitory peptides and have
potential in antihypertensive therapy177,216.

4.1.2

The effect of probiotic administration on adipokine signaling

The role of adipokine signaling in cardiovascular health is of great interest as a potential
therapeutic target, as clinical and animal studies suggest that leptin production and
circulation is upregulated in CVD47,52,57,59,196. Leptin, a 16 kDA peptide, is widely known
for the important role it plays in energy metabolism and food intake. Receptors in the
hypothalamus interact with leptin to cause an overall feeling of satiety, resulting in food
intake inhibition and an increase energy expenditure56. Mutations in the leptin gene, ob,
cause obesity in mice, where knock out animals are three times as heavy and have a fivefold increase in body fat content compared to wildtype217. Similar to insulin,
complications in leptin signaling have become a major issue with obesity. Insulin
resistance caused by obesity drives excessive leptin production, which can also lead to
leptin resistance53. The role of the gut microbiome in adipokine signaling has generated
interest, due to the advances in next-generation sequencing that enable the evaluation of
community-level differences in microbiota composition with a given state of disease218.
16S rRNA sequencing of the gut microbiota of leptin-deficient mice has revealed a major
reduction of the Bacteriodetes phyla and increase in Firmicutes219, similar to the gut
microbial profile of obese individuals67,86. The role the constituent bacteria in each phyla
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plays in the pathogenesis of obesity is not well understood, and attempts to identify
particular species directly involved in obesity are ongoing.
One theory relates to the emerging concept of the microbiome-gut-brain axis. There is
indirect and direct evidence that bidirectional signaling mediated by the gut microbiota
occurs between the gut and the brain. Altered composition of the gut microbiota has been
clinically reported in patients with autism and short-term improvement of symptoms are
reported with antibiotic treatment88,96. Psychiatric symptoms of stress and anxiety trigger
flare-ups in irritable bowel syndrome and inflammatory bowel disease patients220,221.
Animal studies on the gut-brain axis have provided direct evidence for a role of the gut
microbiota. Germ-free animals have lower corticosterone levels in response to stress and
display less stress and anxiety-like behavior than animals colonized with specific
pathogens. The colonization of commensal bacteria in the germ-free animals resulted in a
normalization of these behaviours222. The possibility exists that similar gut-derived
influences on the brain may involve adipocytes and leptin signaling in the hypothalamus.
A way to investigate this would involve monitoring the leptin levels and food
consumption of germ-free, specific pathogen, and/or probiotic-colonized mice with and
without mutations of the leptin gene, ob. Depending on the composition or manipulation
of the gut microbiota composition, there may or may not be a difference in leptin-related
food consumption and energy metabolism.
In addition to metabolism, leptin is involved in cardiovascular health. It is considered a
deleterious hormone in HF223. High levels of circulating leptin are common in HF
patients, and leptin activity exacerbates inflammation and hypertrophy52,57,59,196. While
the cardiac pathologies associated with leptin are often tied to obesity, the deleterious
effect of leptin in HF can also occur independent of obesity224. This is likely because
leptin is not exclusively produced by adipose tissue, but also by the heart56. The study
performed by Lam et al.180 revealed that pre-administration of L. plantarum 299v prior to
I/R in the heart significantly reduced circulating leptin levels and ischemic injury to the
heart. The cardioprotection conferred by L. plantarum 299v against ischemic injury was
abolished when leptin was administered to the rats prior to the surgery. This indicates a
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pivotal role of leptin in the mechanism of action of L. plantarum 299v against ischemic
injury.
In the present CAL model for HF, it is apparent that L. rhamnosus GR-1 also conferred
an anti-leptin effect. As expected, blood analysis indicated a significant increase in
absolute plasma leptin concentration after 6 weeks of sustained CAL. This was entirely
blocked with L. rhamnosus GR-1 administration, resulting in positive outcomes in
cardiac function. Theoretically, a significant decrease in leptin should cause a reduction
in satiety and increase in food consumption. Probiotics have reduced circulating leptin
levels in other models of disease, but it is rarely without any associated change in body
weight or adiposity225-227. There was no observed weight gain or change in eating habits
in animals with reduced plasma leptin in this study.
We surprisingly saw a trend that L. rhamnosus GR-1 administration to sham-operated
animals caused an increase in absolute plasma leptin, to the same level as CAL-operated
animals without L. rhamnosus GR-1. As there was no indication of under-eating in these
animals, nor any significant weight loss, presumably this increase in leptin did not result
in any adverse metabolic outcomes. This result makes it difficult to speculate on the role
of leptin in this model, however clinical studies indicate that the concentration of leptin
relative to adiponectin is a more important marker for CVD than the absolute plasma
leptin concentration 223,228. The substantial increase in plasma leptin to adiponectin ratio
in CAL-operated animals was significantly attenuated by L. rhamnosus GR-1
administration. The was still an increase in the leptin to adiponectin ratio in shamoperated animals administered L. rhamnosus GR-1 compared to the control, however this
difference was not statistically significant. It is possible that there is a healthy range of
activity of these two adipokines that is influenced or managed by L. rhamnosus GR-1.
Physiologically, the relationship between leptin and adiponectin is somewhat mutually
exclusive; when one is upregulated, the other is downregulated, and the two generally
have opposing systemic effects. However, considering the complexity of the diseases
these adipokines are associated with, including HF, it is difficult to ascertain the cause
and effect relationship between L. rhamnosus GR-1 and leptin activity. This study
indicates that the attenuation of HF by probiotic administration was in part mediated by
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reduction of leptin activity, however it cannot be determined from this data whether
leptin levels were reduced because of the improved parameters of cardiac function and
remodeling, or whether it was the reduction of circulating leptin by probiotics that helped
improve the cardiac abnormalities. Future studies could include exogenous administration
of leptin along with probiotics, or the use of leptin deficient animals.

4.2
Exploring the mechanisms responsible for the
attenuation of HF by L. rhamnosus GR-1
The CAL animal studies were designed to investigate whether probiotics attenuated HF,
and if so, whether it was via modulation of the existing gut microbiota and/or
inflammatory signaling. In addition, mechanistic in vitro studies were performed on
primary cardiomyocytes isolated from the neonatal rat heart.

4.2.1

The role of cytokines

The initial inflammatory response to MI is a pre-requisite for the healing process of
phagocytosis and scar formation to take place, however, chronic inflammation can be
detrimental as it causes additional cell death and promotes cardiac remodeling24. HF is
often associated with chronic inflammation in which pro-inflammatory cytokine
parameters are elevated in patients222. IL-6, TNF-α, fractalkine are among the several of
the pro-inflammatory cytokines that positively correlate to severity of MI, impaired
survival post-MI, as well as poor short-term and long-term clinical outcomes229.
Reducing inflammation in HF patients is important for managing disease progression.
Animal experiments have suggested that anti-inflammatory therapies might be beneficial
in HF, however translating these findings to a clinical setting has been widely
unsuccessful, as there is likely no one common inflammatory pathway involved230. While
the use of probiotics as an anti-inflammatory therapy for HF has not been explored, there
are many studies showing that certain probiotic strains, including L. rhamnosus GR-1,
confer anti-inflammatory effects231-233. In the gut epithelium, probiotics interact with tolllike receptors and transcription factors that regulate widespread inflammatory responses,
resulting in benefits for gastrointestinal diseases such as inflammatory bowel disease and
necrotizing enterocolitis137,138 and also for distal inflammatory diseases such as
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rheumatoid arthritis139. Genetically engineering probiotics for the production of antiinflammatory factors, such as IL-10, is a strategy for colonic inflammation that is
currently under clinical investigation29.
It was hypothesized that probiotics could improve outcomes of HF in the CAL study by
reducing systemic inflammation. At the completion of the 6 week-long study, the blood
levels of nine pro-inflammatory cytokines (fractalkine, GRO/KC, IFN-γ, IL-1α, IL-6,
MCP-1α, MIP-1α, RANTES, and TNF-α) were analyzed. No change in blood cytokine
levels was found with respect to the CAL surgery, nor was there any influence of L.
rhamnosus GR-1 treatment on serum cytokine levels. This was a surprising result,
considering that all other indices of HF measured were positively correlated the CAL
surgery. However, the findings corroborate with those published by Lam et al.180 who
reported that L. plantarum 299v administration did not affect the blood levels of 22
cytokines measured in their I/R model. A limitation in that study was that these bloodborne factors were analyzed only at the end-point. Blood sample collection from rats can
be troublesome and invasive, and it is possible that the associated stress will influence
other parameters under investigation. It is recommended to not to take blood samples
more than once every two weeks, and many popular methods, such as retro-orbital
bleeding, require anaesthetization234. For these reasons, we decided to only collect blood
samples by terminal bleeding at sacrifice. Without collecting blood samples before
surgery, immediately post-surgery, or mid-trial, the serum cytokine analysis is limited to
only end-point data, and it cannot be concluded that neither CAL surgery nor probiotics
influence inflammation in this model.

4.2.2

The role of the gut microbiota

The gut microbiome is a rich ecosystem that plays a critical role in our health. Beginning
from the early postnatal days of colonization, the gut microbiome develops into a
synergistic organ in which a specific equilibrium is required for optimal health. The
microbes of the gut perform a multitude of functions, including nutrient breakdown,
vitamin and metabolite production for absorption across the intestine68, as well as
immune system activation and modulation82.
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The core gut microbiota develops rapidly after birth and is generally considered stable
throughout adulthood, however perturbations such as those brought on by environmental
stress, disease, altered diet, can drastically alter the core gut microbial profile82. Dysbiosis
has an impact on disease and has been associated with a wide range of conditions, from
C. difficile infections70 to autism88. Common therapies for restoring microbial equilibrium
involve the use of nonspecific antibiotics, however the inability of these drugs to
discriminate between ‘good’ and ‘bad’ bacteria emphasizes the need for alternative
therapies. Some animal studies have demonstrated that probiotic therapy can restore a
dysbiotic gut microbiota associated with obesity159, yet other studies, including human
clinical trials, have shown that probiotic administration results in neither probiotic
colonization nor any over dramatic changes in species composition of the gut160.
In the 6 week-long CAL study, we performed 16S rRNA next-generation sequencing on
gut digesta samples for with 2 main objectives: (i) to determine whether or not the gut
microbial profile of healthy animals differs from those with HF, and (ii) to determine
whether or not the effects of probiotic administration on the outcome of HF is conferred
by an alteration of the gut microbial composition.
Among the 242 OTUs identified in the 16s rRNA next-generation sequencing analysis, L.
rhamnosus GR-1 was not detected in cecum digesta samples. In order to maximize
accuracy and avoid erroneous OTU assignment, the cut-off for detection and taxonomic
assignment for each sample was set at a minimum 0.5% species abundance. The fact that
L. rhamnosus GR-1 was not detected in this analysis indicates that it represents less than
0.5% of the total species present in the cecum. Considering the overall diversity and
richness of the gut microbiota (1014 organisms), the daily dose of 109 CFU of L.
rhamnosus GR-1 would account for only 0.001% of the total bacteria present, therefore
we were not surprised that GR-1 was not detected using the Ion Torrent platform. It is
apparent that L. rhamnosus GR-1 cause a significant change in the composition of the
cecum microbiota, at the community level. It is possible that the phenotype observed with
probiotic administration occurs due to a direct interaction between the probiotics and the
heart. While bacterial translocation across the epithelial border may occur in patients with
compromised gut barrier permeability235, it is not thought to have occurred in this model.
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Despite the cardiac injury sustained by CAL, the rats were otherwise in good health
without any symptoms of gastrointestinal dysfunction. Instead, it is more likely that the
probiotics produce one or more soluble factors, such as a small protein or metabolite that
crossed the gut epithelial barrier and entered the blood circulation. Upon reaching the
heart, or via factors that affect the heart, this factor(s) could potentially be responsible for
the attenuation of cardiac remodeling, hypertrophy, and HF in the rat.

4.2.3

The direct interaction of probiotics with cardiomyocytes in
vitro

To further investigate the mechanisms responsible for the attenuation of HF by L.
rhamnosus GR-1 and L. plantarum 299v, co-culture experiments were designed using
neonatal rat ventricular cardiomyocytes (NVCM). These terminally differentiated
primary cells are often used for in vitro HF models because of their ideal response to
pharmacological manipulation1. It was hypothesized that the addition of live probiotic
cells to NVCM culture would confer cardiac benefits. The initial simple assays were
performed to determine NVCM viability after exposure to live probiotic cells. Cell lines
that are physiologically accustomed to bacterial exposure, such as gut epithelial cells,
gingival cells, skin cells, or vaginal cells, may be tolerant to bacterial co-culture in vitro.
However, in culturing cells derived from otherwise “sterile” organs, great measures are
taken to avoid bacterial exposure. In the case of NVCM, these cells are not
conventionally exposed to bacteria. To prevent contamination, antibiotics were added to
the culture media. We were initially unsure, therefore if either the NVCM or probiotics
would survive the co-culture conditions, as reports of similar co-culture techniques using
NVCM are scarce in the literature. The heart is considered a “sterile” organ, in which
encounters with bacterial species can result in serious infections. We were impressed to
find that the addition of 5 x 107 CFU of L. rhamnosus GR-1 to NVCM had no adverse
effects on cell viability or function. In fact, with the daily replacement of cell culture
media and L. rhamnosus GR-1 cells, spontaneously beating NVCM were maintained for
as long as seven days, which is the recommended duration of culture for these primary
cells1. The inclusion of antibiotics in the cell culture media also seemingly did not affect
L. rhamnosus GR-1 cell viability, as its cells were cultivated from the media after 24
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hours. These encouraging preliminary assays seemed to support the hypothesis that
probiotics provide a direct benefit to cardiomyocytes, independent of the gut.
To employ a model relevant to HF, PE was to induce hypertrophy in NVCM. This αadrenergic receptor agonist is an agent commonly used in models of cardiac
hypertrophy35,236,237. The effect of PE on NVCM was evaluated by calculating the cell
surface area and gene expression of the hypertrophic markers ANP and aSKA 24 hours
after PE exposure. To closely mimic the design of the CAL studies, each probiotic
treatment was administered to NVCM immediately following PE exposure. Physical
analysis on the change in cell surface area indicates that L. rhamnosus GR-1, L.
plantarum 299v, and S. salivarius K12 administration blocks PE-induced hypertrophy in
NVCM over 24 hours, and normal NVCM morphology and function is maintained. This
phenotype was seen for a range of concentrations of L. rhamnosus GR-1, suggesting a
strong potency of the treatment. The anti-hypertrophic activity of L. rhamnosus GR-1
was confirmed by a significant attenuation of the PE-increased gene expression of both
ANP and aSKA. This supported the hypothesis that the cardiac benefits conferred by
probiotics in vivo and in vitro is not strain specific. Interestingly, NVCM co-cultured with
Lactobacillus reuteri RC-14, a vaginal isolate, generally did not survive the assays.
Attempts to isolate L. reuteri RC-14 from the culture media after the 24 hour co-culture
were unsuccessful, indicating that the co-culture conditions were not viable for L. reuteri
RC-14 either. This showed that not all probiotics have the same mechanism of action or
confer the same health benefits. It is possible that the L. reuteri RC-14 co-culture is nonviable because it produces hydrogen peroxide in culture134.
It was presumed that live probiotic cells are required to confer salutary cardiac benefits.
Dead L. rhamnosus GR-1 or L. plantarum 299v cells were not administered in the CAL
studies, however in NVCM co-culture experiments, HK L. rhamnosus GR-1 cells were
administered. L. rhamnosus GR-1 cells were removed from the PCM, washed, and
incubated at 80°C. After unsuccessfully cultivating these cells on MRS agar, they were
determined non-viable. A loss of anti-hypertrophic activity was noted, as determined by
the fold change in cell surface area and ANP gene expression. However, the difference in
the NVCM hypertrophy of live GR-1 cells compared to HK GR-1 cells was not
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statistically significant for all parameters measured. One possible explanation is that L.
rhamnosus GR-1 formed a heat-stable biofilm and thus undetectable live organisms were
still present. Another is that anti-hypertrophic factors produced by L. rhamnosus GR-1
were present despite the heat treatment. Further experiments are warranted to explain the
results.
It is apparent that probiotic strains can provide direct protection to cardiomyocytes
against hypertrophy. While cardiomyocytes will not encounter such high densities of live
probiotic cells in vivo, soluble factors produced by the lactobacilli may cross the gut
epithelial barrier into the blood and reach the heart.
There is evidence that L. rhamnosus GG produces a soluble protein with anti-apoptotic
activity that is directly protective against I/R-associated injury to the heart178,179. We were
able to obtain a knock out mutant strain for this protein in L. rhamnosus GR-1
CMPG10200. Its absence did not affect the outcome on the NVCM surface area, as
CMPG10200 conferred an anti-hypertrophic effect identical to the wild type L.
rhamnosus GR-1. Based on these results, it was decided not to continue analysis on this
mutant, but to analyze the effect of NVCM co-culture with PCM, void of live probiotic
cells.
The L. rhamnosus GR-1 supernatant has been studied in other settings, and found to
contain some biosurfactant238,239. In the present studies, when lactobacilli whole cells
were completely removed, the PCM conferred a similar effect against PE-induced
hypertrophy in terms of cell surface area and gene expression of ANP and aSKA, albeit
to a lesser magnitude than the whole cell preparation. This indicated that L. rhamnosus
GR-1 produces a factor that prevented PE-induced hypertrophy in NVCM. It was
hypothesized that the responsible factor was a protein, and treated the PCM with trypsin,
with the result that the effects on surface area and ANP gene expression were completely
lost. While this effect was not as marked in aSKA, there was a slight increase in gene
expression compared to regular PCM.
The role of proteins derived from Lactobacillus rhamnosus GR-1in preventing
hypertrophy was further examined by centrifugal filtration based on molecular size
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exclusion. Filtration of the PCM through 20 nm pore size filter did not result in a
significant difference in the average NVCM surface area compared to untreated cells,
however the fold change in surface area indicated that anti-hypertrophic activity was lost
in both the filtrate and retentate. This suggested that there is may be more than one
protein responsible for attenuating hypertrophy which cannot be effectively separated by
size. It was hoped to elucidate the heat sensitivity of these potential proteins by
incubating the PCM at a high temperature, typically heat stable proteins are smaller in
mass. Trypsin acts indiscriminately on proteins by cleaving peptide chains, but heat
denaturing a solution may result in variable outcomes, depending on the nature of the
proteins present. Large proteins are typically heat sensitive and denature at lower
temperatures than smaller ones. Small, heat stable proteins (less than 20 kDa) have the
potential to maintain function after heat incubation and are reported to be produced by
various lactobacilli strains240,241. In these experiments, heat denatured PCM did not
significantly attenuate the PE-induced increase in cell surface area (fold change) or
increase in ANP gene expression, indicating a loss in anti-hypertrophic activity. This may
be due to the destabilization of the protein(s) by the heat treatment. There was no
difference in gene expression of aSKA with heat denatured PCM compared to regular
PCM. These mixed results might suggest that the PCM affects ANP expression
differently than aSKA, or that is more than one protein involved.
There was a difference in the magnitude of the change of gene expression in ANP
compared to aSKA, depending on the nature of the PCM treatment. Both of these
hypertrophic markers are expressed during prenatal cardiac development and then are
downregulated after birth242,243. Baseline expression of ANP and aSKA in NVCM is
higher than adult cardiomyocytes and gene expression can be induced in both cell types
by hormonal and hemodynamic stimuli as well as pharmacological hypertrophic
agents242. The signaling mechanisms and pathways for ANP and aSKA differ from one
another, and they are not equally as responsive to some stimuli. As discussed earlier,
ANP is a vasodilator that becomes active in response to hypertension242. aSKA is
involved in muscle formation and is associated with cellular growth243. Hypertrophic
phenotypes, therefore, may feature activated ANP expression, while aSKA is not
induced243. The difference lies in the nature of the stimulus used to induce hypertrophy.
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While PE has shown to induce both ANP and aSKA expression in several models of
cardiac hypertrophy207,237,244, other factors may affect the complex and diverse signal
transduction pathways. In the present studies, it is possible that PCM interferes with the
signaling pathway for PE-induced aSKA gene expression, while ANP is unaffected.
Additional assays can be used to confirm hypertrophy, such as cellular leucine
incorporation as a marker for protein synthesis. To continue these mechanistic studies, a
comprehensive functional analysis of the L. rhamnosus GR-1-derived PCM should first
be performed in order to understand exactly what factors are present in the PCM.
The main limitation to the design of the NVCM co-culture experiments was the
availability of NVCM. These primary cells were kindly harvested and provided by the
Karmazyn lab, however Dr. Karmazyn’s own projects understandably took precedence
over this one. The inability to pass and store these cells, as they are already terminally
differentiated and do not divide, meant that the use of NVCM for these co-culture
experiments was entirely dependent on the availability of fresh cells provided with each
harvest. The best attempts were made to match the treatments for cell surface area
experiments to the gene expression experiments in order to confirm the anti-hypertrophic
activity of probiotics. Given the limited availability of cells, this was not always
achieved. With better access to NVCM, future co-culture experiments and treatments
should include dose and time-dependent trials, and additional manipulation of the PCM.
In spite of the limitations, these in vitro NVCM co-culture experiments provided the
foundation for future research into exploring the mechanism behind the attenuation of HF
by probiotics. The next step for this model would be to test the ability of lactobacilli
factors to cross an epithelial barrier using a transwell apparatus. These experiments will
be required in order demonstrate that the anti-hypertrophic factors derived from L.
rhamnosus GR-1 are able to pass through the gut and access the heart.
As schematic diagram of the potential mechanism of action of the probiotic in vivo is
displayed in figure. This diagram summarizes the hypotheses that were tested in this
thesis project and the remaining questions that are left to be answered.
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Figure 21: Schematic diagram depicting the potential mechanism of action of probiotics
at the gut epithelium.
1. Probiotic cells arrive at the intestinal epithelium and produce a soluble factor through
metabolic processes. 2. The soluble factor is transported across the epithelial barrier via
active or passive transport, and enters blood circulation. 3. The portal venous system
transports the soluble probiotic products via the liver to the heart. Along the way, there is
potential interaction with cholesterol and bile acids, and cytokines and hormones in the
blood. The probiotic products then may arrive at the heart via the vena cava and provide a
direct therapeutic benefit to the heart.
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4.3
Clinical implications and the potential for probiotic
therapy for heart failure patients
Probiotics represent one of the fastest growing consumer items on the functional food and
nutraceutical market today245. While researchers and regulatory agencies across the
world emphasize the importance of validating efficacy claims made by manufacturers,
there unfortunately still exists a multitude of products with unsubstantiated claims and
misleading applications for use. In order to ensure consumer confidence, rigorous clinical
trials are required before a probiotic product can gain approval for therapeutic use. To
date, Health Canada has approved only one probiotic product with cardiovascular health
claims. This product, Cardioviva™, contains 2 billion CFU of encapsulated Lactobacillus
reuteri NCIMB 30242 and has been clinically proven to lower LDL-cholesterol levels by
11.6% in hypercholesterolemic adults246. This product represents decades of research and
development into validating the activity of bile salt hydrolase and cholesterol
sequestration by lactobacilli that has been widely reported in the literature.
Another benefit of probiotic therapy is that cases of adverse effects are very rare. For
both Cardioviva™ and GoodBelly containing Lactobacillus plantarum 299v, the
potential side effects are gas and bloating within the initial days of consumption. L.
rhamnosus GR-1 has been notified and accepted by the American Food & Drug
Administration and has been used extensively for the maintenance of a healthy vaginal
microbiota and for lowering the risk of bacterial vaginosis and recurrent urinary tract
infections without side effects 122,134,183,231. With the safety of probiotic use established,
future research into the mechanism of action, strain specificity, and dose and time-course
regimes should be prioritized.
A plethora of probiotic products are available to consumers and it is imperative to
thoroughly characterize the benefits of administration for HF before recommending
particular products in a clinical setting. The data presented in this thesis hopefully
represents a seminal point in therapy for HF. Given the relatively safe track record of
probiotics247 it should be relatively easy to test this concept in clinical settings and verify
that these outcomes are not rat specific. With the extreme unlikelihood of any adverse
drug interactions, it is possible that probiotics can be used in addition to the current drugs
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available for HF. Furthermore, the evidence that sterile PCM can confer antihypertrophic effects may provide a natural supplement route, albeit without any health
claims. Whether or not probiotics have an additive effect to conventional HF medication
remains to be seen. Such combination testing would be interesting to conduct in an
animal model.

4.4

Conclusions

Several conclusions can be made from the results of the studies presented in this thesis,
all of which should be considered in the wider context of novel approaches to treating
HF:
(1) Oral probiotic administration immediately following myocardial infarction
reduces the severity of HF in the rat. This is based on the measurement of several
parameters that are similarly used as indices of HF in a clinical setting. The
administration of two different species of probiotic Lactobacillus exerted identical
cardiac benefits, to a drug-like effect. This implies that probiotic administration
post-myocardial infarction may be a novel treatment strategy for HF.
(2) The salutary effect of oral probiotic administration on the heart occurs
independent of the composition of the gut microbiota. This is based on the 16S
rRNA gene next-generation sequencing analysis in the CAL study and the coculture experiments evaluating the direct interaction of probiotic cells with
NVCM. These findings imply that probiotics function as they pass through the
intestine and produce effects that directly affect the heart.
(3) Lactobacillus rhamnosus GR-1 produces one or many soluble factors in broth
culture that independently confers an anti-hypertrophic benefit to cultured
NVCM. This suggests that the attenuation of HF by probiotic administration
might occur primarily through a reduction of cardiac hypertrophy and ventricular
remodeling and based on in vitro experiments, it is likely that this antihypertrophic factor is a protein.
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